Categories
Report

BRAND NEW NASDAQ: VUZI ON WATCH!

Vuzix logo (PRNewsfoto/Vuzix Corporation)

OUR NEW PROFILE IS:   (NASDAQ: VUZI)

__________

VUZIX IS A PIONEER IN WEARABLE COMPUTING, AUGMENTED REALITY, OPTICS AND DISPLAY ENGINES AND HAS BEEN DELIVERING SOLUTIONS TO CUSTOMERS FOR OVER 20 YEARS

VUZI IS SITTING WITH JUST OVER $73 MILLION IN CASH AS OF DECEMBER 31

VUZIX ACHIEVES RECORD SMART GLASSES SALES IN Q1 2023

FOR THE FULL YEAR ENDED DECEMBER 31, 2022, TOTAL REVENUES WERE $11.8 MILLION

BACK IN MARCH OF 2023, DAWSON JAMES SECURITIES ANALYST, JAMES MCILREE, REITERATED HIS $15.00 TARGET ON VUZI

CHECK OUT THE INVESTOR PRESENTATION HERE

*****BREAKING NEWS YESTERDAY*****

_____________________

Hello Everyone,

We want you to take a look at a Tech company that already has a massive following and a lot of notoriety in the media on top of several other major catalysts.  This already has their foot in the door with several Fortune 100 companies and are sitting with over $70 Million in cash and generated almost $12 Million in revenue last year.  They also received a $15 Price Target which is over 400% above it’s current levels.

This is one that you will want to research right away!

Pull up Nasdaq: VUZI Immediately. 

This is a company that has been on a tare coming off of the CES, the worlds premiere electronics show.  They debuted their Ultralite AR Glasses.  Their have been a few positive articles from prominent publishers like the Wall Street Journal and Tech Times.  These are glasses that have ordinary-looking plastic frames with a tiny projector tucked in one stem and a tiny battery and Bluetooth radio in the other. It also has Vuzix’s waveguides which is a layer in the glasses that bends the projector’s light into your line of sight.

I know I laughed the first time I really heard of a Tesla.  The concept of an electric car sounded ridiculous and I didn’t think that anyone would really buy them. I also never thought that re-charging could never be made something that is practical and easy to do.  Now if you drive down a California highway it seems like every 7th or 8th car could be a Tesla.  They are everywhere.

I really don’t think it would be a far-fetched statement to say that some of the concepts that VUZI have rolled out and AR Glasses could be part of our everyday life in the near future.  There is a whole generation getting older that grew up with some of the advanced technology that we use today. They didn’t have to learn it as adults.  It was part of their upbringing.  This isn’t something that will be unique to AR.  I think it will impact all areas of technology.

The company itself has a lot going on.  Vuzix is a leading supplier of Smart Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. They have offices in Rochester, NY, Oxford, UK, and Tokyo, Japan and were founded back in 1997.  The Company’s products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 274 patents and patents pending and numerous IP licenses in the Video Eyewear field. Moviynt, an SAP Certified ERP SaaS logistics solution provider, is a Vuzix wholly owned subsidiary. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2023 and several wireless technology innovation awards among others.

Their AR wearable display devices are worn like eyeglasses or attach to a head worn mount. These devices typically include a wearable computer, cameras, and sensors that enable the user to view, record and interact with video and digital content, such as computer data, the Internet, enterprise data, social media or entertainment applications. Their wearable display products integrate micro-display technology with our advanced optics to produce compact high-resolution display engines, less than half an inch diagonally, which when viewed through our Smart Glasses and AR products create virtual images that appear comparable in size to that of a computer monitor or a large-screen television. This includes the representative forms such as augmented reality (AR), mixed reality (MR) and virtual reality (VR) and the areas interpolated among them. Extended reality (XR) is a term referring to all real-and-virtual combined environments. Their wearable display products cover the entire spectrum from “the complete real” to “the complete virtual” in the concept of reality–virtuality.

They believe that their waveguide optics and display engines offer a number of significant advantages over other wearable display solutions, including higher contrast, greater power efficiency, less weight, more compact size, and high brightness images for use outdoors. They also believe that our waveguide optics give them a substantial advantage over competitors’ optics, including other waveguides, because their solution allows them to produce optics that are fully transparent when off while also delivering the high brightness required for AR and enterprise Smart Glasses applications.

They  believe that key growth areas for us are the enterprise, medical, consumer electronics, OEM, defense and security markets. They are addressing most of these markets by developing and selling their own finished products and building a growing eco-system of software and services internally and with their value added resellers, or VARs, developers and end customers. Another potential channel to these markets they are developing includes supplying mass production of waveguide optics and display engines to select third parties to use in their products.

They believe that their waveguides and compact display engine technologies are a key differentiator for enabling next generation AR and Smart Glasses hardware for the enterprise and consumer segments because they will ultimately allow them to make HMDs nearly indistinguishable from regular eyeglasses.

They have developed their own intellectual property portfolio that includes patents, over 22 years of manufacturing know-how, software, proprietary processes, materials and equipment to create high performance waveguides, and near-eye display products. They believe our technology, intellectual property portfolio and position in the marketplace give them a leadership position in AR and Smart Glasses products and waveguide optics and display engine technology.

VUZI EXPLODED AT THE END OF DECEMBER  FROM BELOW IT’S CURRENT LEVELS TO OVER $6

VUZIX ACHIEVES RECORD SMART GLASSES SALES IN Q1 2023

– Preliminary Q1 2023 Revenue Has Topped $4 Million

ROCHESTER, N.Y., April 10, 2023 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that first quarter 2023 sales of AR smart glasses were at a record level, driven by use for enterprise and medical applications. As a result, the Company has also announced that preliminary revenue for its first fiscal quarter of 2023 has surpassed $4.0 million, more than 60% ahead of the prior year’s first quarter’s revenues of $2.5 million.

Vuzix M400 smart glasses (PRNewsfoto/Vuzix Corporation)

The Company’s preliminary and unaudited financial revenue results and the related comparison to the prior year’s period included in this release, are subject to the completion of the Company’s financial close and other procedures and finalization. Accordingly, actual financial results to be reflected in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, may differ from the preliminary and unaudited revenue results presented herein.

SALES PROGRESS

MEDICAL APPLICATIONS

PRODUCTS


VUZI showcased a robust lineup of smart glasses at this year’s Consumer Electronics Show, held in Las Vegas, Nevada. In addition to displaying its new CES 2023 Innovation Awards winning Vuzix Ultralite™ AR smart glasses OEM design, which uses Vuzix’ industry leading waveguides and the latest microLED displays, Vuzix demonstrated its M-Series, Vuzix Blade 2™ and Vuzix Shield™ AR smart glasses.

Vuzix Blade 2

Vuzix® Corporation’s innovative Vuzix Blade 2™ smart glasses (shown above) connect frontline workers with critical AR systems, enabling hands-free, heads-up access to data and remote expertise, all in a sleek, lightweight form factor.

Allowing you to keep your eyes protected with an ANSI Z87.1 certification while maintaining focus on your work. Ultrabright waveguide optics merge digital instructions onto real-world tasks, removing distractions and vision occlusion, ultimately reducing error rates and making your connected workforce more effective.

The World’s First Advanced Binocular Waveguide Built For Industrial Use. (Shown Below)Vuzix Shield™ is a revolutionary leap for enterprise AR smart glasses. Lightweight, stylish, prescription ready safety glasses and powerful 8-core CPU combine to deliver a singular wearable experience.

(Image source: Vuzix)

Connect to the metaverse accessing IT sensors, instructions, or live remote guidance, leaving your hands free. Scan codes with an advanced reader or wirelessly stream video from the field all enabled through voice or touch.

With the world’s first miniature uLED stereo displays, Vuzix Shield connects smart workforces with AR systems for optimized performance, safety and operational efficiency.

Using a Vuzix accessory adapter and a compatible infrared camera, including FLIR cameras, Vuzix M-Series AR smart glasses will allow visitors to see in the infrared spectrum, giving them a heads-up display of what’s normally hidden from view. Infrared video can also be broadcast over Zoom to enable team inspections.

Using Vuzix Blade 2 AR smart glasses, visitors will be put in charge of solving a real-life industrial challenge, the resetting of an electric power station, using on-glasses video and a set of work instructions.

Using Vuzix Shield AR smart glasses, visitors will be put in the role of a quality check inspector checking one of the most beautiful bikes ever, a real MV Agusta Superveloce 8001, to perform a scan for equipment recalls.

Using Teamviewer Frontline software running on Vuzix M400 AR smart glasses, visitors will be able to explore how major distribution centers drive efficiency improvements every day.

Finally, as part of its OEM offerings, Vuzix will be showcasing the 2023 CES award winning, sleek, AR smart glasses reference design called Vuzix Ultralite.

Offering fully customizable form factors, optics and more, Vuzix OEM solutions produce smart glasses and components that are miles ahead of the pack to support the worldwide adoption of AR.

“We keep expanding and improving the competitiveness of our smart glasses family of products. We enter 2023 with the strongest product lineup in our history, one that continues to attract an expanding number of blue chip customers across a wide range of industry verticals,” said Paul Travers, President and CEO of Vuzix.“We intend to remain focused on offering solutions that increase worker productivity, interactivity and safety while reducing errors and improving our carbon footprint.”

VUZIX ULTRALITE

AN OEM SMART GLASSES PLATFORM LIKE NO OTHER

Vuzix Ultralight™ Smart Glasses

The Vuzix Ultralite™ AR Smart Glasses Platform is a go-to-market ready, turnkey offering designed to fast track client AR solutions into production. Weighing in at a mere 38 grams, super power-efficient with up to 48 hours of run time on a single charge, and packing an impressive waveguide to display information from your phone hands-free to your eye, Vuzix Ultralite OEM platform is a blueprint for the world’s most fashion forward smart glasses.  

TRUSTED PROPRIETARY TECHNOLOGY FROM VUZIX

Advanced monocular waveguide optics, combined with our custom micro display engine, create a crisp, transparent image that can deliver all the important information on a user’s smartphone/watch, hands-free right before their eyes. Prescription ready with multiple sizes and an array of component combinations, the Vuzix Ultralite OEM platform makes available our extensive manufacturing capabilities and patent-protected leadership position in both waveguides and custom display engine solutions.

THE POWER TO DEPLOY YOUR AR SOLUTION AT SCALE

The Vuzix Ultralite OEM platform is designed to enable leading consumer technology firms to accelerate deployment of AR smart glasses solutions to the masses. Our manufacturing facility in Rochester NY is an ISO 9001:2015 facility that includes Class 6 and Class 7 clean room enclosures ensuring the highest levels of product quality and precision. All Vuzix OEM components are designed and manufactured in the USA, leveraging proprietary advancements in waveguide technology protected by our extensive IP portfolio. 

VUZIX ULTRALITE OEM PLATFORM BENEFITS

  • Puts your smartphone’s alerts, messages, and custom applications content heads up in front of your vision.
  • Get hands free access to important information, from language translation and closed captioning, to directions, to health and workout status, to messaging and much, much more.
  • Designed to work hand to glove with both Android and iOS phones, Vuzix Ultralite is the reference design for the perfect smartphone accessory.
  • Virtually endless configuration options around size, color, form factor and optical setup to set your solution apart.
  • Vuzix is working with the world’s leading consumer electronic technology companies to bring lightweight, affordable smart glasses solutions to market.  
Dawson James Logo

BACK IN MARCH OF 2023, DAWSON JAMES SECURITIES ANALYST, JAMES MCILREE, REITERATED HIS $15.00 TARGET ON VUZI

Here’s the thing. From Tuesday’s closing valuation, that provides VUZI with over 300+% potential upside.

Here’s a few key highlights from the report: 

  • Commercial opportunities could be catalyzed by Apple’s long-awaited entry into the market with an AR/VR headset. Vuzix offers an ultralite smartglass system for the OEM market that utilizes the company’s proprietary waveguide solution and custom microdisplay engine. A consumer smartglass solution is being pursued by many of the major tech companies including Meta, Apple and Alphabet. We expect a robust market will emerge over the coming years and Vuzix is positioning itself to serve that space.
  • In the defense market, the company has development deals with a handful of major defense contractors on waveguide-based products. Lead times can be extended, but once deployment begins production runs can be long and very profitable. We estimate typical production contracts could generate $10 to $15Mn over a multi-year time frame. Vuzix is also working with multiple customers on supplying waveguides for the consumer market. There is upside to our sales projections from these waveguide projects.
  • The company has unique expertise in waveguide design and manufacturing and is expanding its waveguide capacity both in response to customer indications of interest and to make itself the number-one choice of waveguides in the OEM market for industrial and consumer use. This in-vest-ment is modest, a few Mn dollars, and will expand capacity, lower costs and enable a more robust feature set than the current product. We believe Vuzix can be one of the leading suppliers of waveguides and that this investment will enhance that capability. 
  • Price Target Methodology. Our $15 price target values the company’s smart glasses and waveguide businesses at a significant discount to recent market transactions in the smart glasses space of $775M to $2B and $500M to $542M in the waveguide market.

Check out the full report here.

VUZIX CEO ADDRESSES SHAREHOLDERS AND ADVANCES BULLISH OUTLOOK FOR 2023

–  Strong revenue growth expected across core smart glasses products, OEM/Engineering services and SaaS software solutions

ROCHESTER, N.Y., April 19, 2023 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today issued a shareholder letter from its President and Chief Executive Officer, Paul Travers. The letter, stated in its entirety below, provides an opening 2023 comment, a recap of 2022 achievements and developments, and then gets into more details about the success drivers regarding the Company’s 2023 growth initiatives and trajectory.

Dear Fellow Shareholders:

I want to share some of our recent Company highlights, outline the strength we are experiencing in general, and share our vision for the future as a leader in the wearable computing, augmented reality (AR) and smart glasses markets.

2023 will be a year of significant growth and strong revenues for Vuzix

In the years leading up to and including 2022, our revenues were primarily derived from our core smart glasses enterprise business. Today we now have revenue growth expectations from three contributing business sources at Vuzix, all revolving around our core smart glasses technology:

  • Core smart glasses products
  • OEM/Engineering services
  • SaaS solutions for logistics and supply chain

Vuzix’ enterprise smart glasses business is now positioned to generate significant revenue growth in 2023. Our newly formed OEM design and manufacturing platform is seeing success and is expected to deliver new revenue growth in 2023, both in the form of engineering services and products. Our SaaS-based logistics solution company, which started generating incremental revenue and customer traction simultaneous with its acquisition last fall, will add to our sales total for the year. With this stronger portfolio of product offerings and services, Vuzix is well positioned to achieve substantial top-line revenue growth in 2023. We believe our first quarter represents a harbinger of the year’s strength with preliminary revenue in excess of $4Mn, as recently announced, rising more than 65% year-over-year versus 2022’s Q1 level, primarily on record sales of smart glasses as a result of enterprise customer growth, adoption and deeper rollouts in the period.

2023 is starting off strong and setting up to deliver strong annual sales

To recap, our first quarter of 2023 is off to a very strong start. We are bullish on our full-year prospects for 2023 with our potential for continuing record revenues from our collective product and OEM engineering services. Anticipated developments for 2023 include:

  • increased deployments in warehousing and logistics;
  • expanding healthcare deployments from existing ISVs and with multiple new customers;
  • further expansion of our sales channels in specific new geographic regions;
  • additional and larger engagements from defense firms that should evolve into longer-term production programs;
  • signing of first agreements with potential OEM and white label firms for our waveguides and display engines;
  • initial deployments of Ultralite-based product by Vuzix or third parties; and
  • increased SaaS revenue from our Moviynt acquisition.

Conclusion

We significantly strengthened our infrastructure along with the breadth and competitiveness of our products and technologies in 2022 and, as a result, we are better positioned for success in 2023 and beyond. We are working across many market verticals — from warehousing and logistics, automotive, pharma and healthcare, to defense and consumer — to deliver industry leading smart glasses and engineering service solutions.

Many people and potential customers today are not yet fully aware of the value of our waveguide intellectual property and production capabilities, and the equally strong position we are working to create on the display engine side. For the broader markets to be successful, waveguide and display manufacturing in volume and at price points that can meet the market requirements critical for success, and Vuzix’ ongoing investments in these areas should uniquely position us to continue leading and delivering on this need. We feel we can honestly say that there are no competitors anywhere close to delivering what Vuzix can offer today, and what we expect to deliver in the near future.

I, and all of us at Vuzix, appreciate your interest, and I am confident 2023 will represent a year of solid progress for Vuzix.

Best regards,

Paul J. Travers

President and CEO

Vuzix Corporation

_____

VUZIX STRENGTHENS ITS GLOBAL SALES AND SUPPORT INFRASTRUCTURE WITH NEW OFFICES AND CORPORATE ENTITIES IN GERMANY AND JAPAN

 Regional cost-effective moves will boost customer service, accessibility, development and support

ROCHESTER, N.Y., April 24, 2023 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced two international infrastructure developments that will allow the Company to better serve existing partners and customers, as well as develop and support new relationships. New offices and corporate entities have recently been established in Germany and Japan, two countries geographically situated to address significant local and regional market opportunities. In addition to improving sales and customer support in these areas, these moves will also reduce overall costs due to the elimination of capital taxes based on the Vuzix parent corporate entity.

(PRNewsfoto/Vuzix Corporation)

To expand its presence in Europe and signal a clear strategic decision to the Company’s European customers and partners, Vuzix has established an EU-based office in Munich, Germany. Munich is a preferred location for the EU offices of many global IT companies, as well as boasting a strong local technology community. The new office, established as Vuzix Europe GmbH*, a 100% wholly-owned subsidiary of Vuzix, will serve not only the EU, but also the Middle East and Africa and will even operate globally in some sales and marketing functions while the Company expands its global footprint.

In Japan, Vuzix has converted its legal designation from a branch to a KK** corporate entity, a 100% wholly-owned subsidiary of Vuzix, an action that will optimize the Company’s tax structure and better allow it to scale its organization under Japanese laws. Additionally, Vuzix has opened a new office in Kyoto, a cultural and geographic hub in Japan which offers faster and more expansive local and international shipping capabilities than Tokyo. As many of Vuzix’ larger Japanese customers are located in the western regions of Japan, the new office in Kyoto will be better positioned to sell to and support these customers.

“These new offices and newly established corporate entities are all about increasing Vuzix’ ability to better serve our customers and partners and show our commitment to these strategic growing markets. We feel this enhances our distinct competitive advantage in these markets with local staffing and fuller country compliance now with effectively local entities involved in and specializing in enterprise AR smart glasses,” said Paul Travers, President and CEO of Vuzix. “Having a stronger regional presence in these key locales provides the customer with increased confidence of the entity they are transacting with and greatly improves our ability to share an enhanced local knowledge, improves customer visibility, quickens our speed to act, and helps streamline our legal and business processes to more cost effectively and faster support and address both existing and new business opportunities.”

*GmbH is an abbreviation of the German term “Gesellschaft mit beschränkter Haftung,” which means “company with limited liability”.
**KK is an abbreviation of the Japanese term “Kabushiki Kaisha,” the most common and recognized type of business entity defined under Japanese law.

VUZIX RECEIVES OEM PURCHASE ORDERS FROM MULTIPLE DEFENSE AND COMMERCIAL CUSTOMERS

ROCHESTER, N.Y., Jan. 10, 2023 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, is pleased to announce the receipt of multiple OEM purchase orders for engineering services and products from three previously undisclosed defense firms and one previously undisclosed commercial customer. These orders, which were all received during the second half of 2022 and partially or fully shipped against before year end, are expected to expand in size over time to the extent each of these programs progresses. A brief description of each of these firms, the names of which cannot be disclosed at this stage of development, and the intended use cases for are as follows.

Vuzix has received multiple OEM orders for its waveguides, displays and systems.

A multinational electronics contract manufacturer has placed multiple orders for Vuzix waveguides and displays to support its development and manufacture of unique vision-based AR glasses.

A US-based leader in technologically advanced and intelligent solutions for the global aerospace and defense industry has given Vuzix an engineering services contract to support the development of a lightweight heads-up display (HUD) replacement for technologies previously supplied by a China-based company. This firm, a top 10 defense contractor, is the incumbent supplier for several existing programs and has turned to Vuzix as a US-based manufacturer of waveguide and display technologies.

A US-based supplier of protective armor and head systems, as well as innovative power supply and management solutions for military and tactical operators worldwide, has placed an order for Vuzix hardware technologies that will support their efforts to design several prototype display systems for the US Navy. Naval teams are currently using ruggedized Android phones but want to move the display to the helmet using Vuzix display technology. This customer plans to deliver its prototypes to the US Navy in pursuit of a design selection that, if successful, could result in volume production contracts over the next several years.

A US-based global leader in personal protection and situational awareness solutions for defense forces, emergency responders, and industrial personnel, has placed an order for Vuzix waveguides and projectors with the objective of adding smart capabilities to their helmet solutions via inclusion of a HUD.

“Our OEM business has continued to steadily expand in 2022 as more and more defense, consumer and enterprise firms are turning to Vuzix for its advanced low-cost waveguide and display solutions, solutions that are designed and manufactured in the United States. With some of these defense firms, we are already discussing much larger development and supply contracts for 2023,” said Paul Travers, President and Chief Executive Officer at Vuzix. “These new relationships further demonstrate the emerging presence of our advanced technologies in next generation system designs.”

NEWS

Apr 24, 2023 9:05am EDT

VUZIX STRENGTHENS ITS GLOBAL SALES AND SUPPORT INFRASTRUCTURE WITH NEW OFFICES AND CORPORATE ENTITIES IN GERMANY AND JAPAN 

Apr 19, 2023 9:42am EDT

VUZIX CEO ADDRESSES SHAREHOLDERS AND ADVANCES BULLISH OUTLOOK FOR 2023 

Apr 12, 2023 9:01am EDT

VUZIX RECEIVES VOLUME FOLLOW-ON SMART GLASSES ORDER FROM ACURAFLOW TO SUPPLY PHARMACEUTICAL CUSTOMER 

Apr 10, 2023 8:52am EDT

VUZIX ACHIEVES RECORD SMART GLASSES SALES IN Q1 2023 

Apr 05, 2023 9:00am EDT

GLOBAL HEALTH TECHNOLOGY PLATFORM PROVIDER PROXIMIE COMMENCES ROLLOUT OF PXLENS USING VUZIX M4000™ SMART GLASSES 

Mar 27, 2023 8:45am EDT

VUZIX SMART GLASSES SUPPORT NEW PARTNERSHIP DESIGNED TO SOLVE GLOBAL HEALTH WORKFORCE SHORTAGES 

Mar 09, 2023 10:50am EST

VUZIX SIGNS DISTRIBUTION AGREEMENT WITH MACE VIRTUAL LABS AND RECEIVES SUBSTANTIAL INITIAL VOLUME SMART GLASSES ORDER 

Mar 06, 2023 3:00pm EST

VUZIX TO PARTICIPATE IN TWO FINANCIAL CONFERENCES IN MARCH 

Mar 01, 2023 4:05pm EST

VUZIX REPORTS 4Q AND FULL YEAR 2022 RESULTS 

Feb 23, 2023 3:35pm EST

VUZIX SCHEDULES CONFERENCE CALL TO DISCUSS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND BUSINESS UPDATE

Feb 22, 2023 11:05am EST

VUZIX ANNOUNCES ANDROID 11 SUPPORT FOR ITS LATEST PORTFOLIO OF ENTERPRISE SMART GLASSES 

Feb 16, 2023 7:30am EST

VUZIX ADVANCES THE VUZIX ULTRALITE™ OEM PLATFORM TO BETTER FACILITATE VISUAL GPT AND OTHER AI FUNCTIONS 

Feb 09, 2023 1:00pm EST

VUZIX ENTERS FORMAL RESELLER RELATIONSHIP WITH OPTAC-X 

Feb 07, 2023 8:15am EST

VUZIX SMART GLASSES HAVE NOW SUPPORTED 40,000 VIRTUAL SESSIONS USING THE RODS&CONES REMOTE ASSISTANCE SERVICE FOR THE OPERATING ROOM 

Jan 31, 2023 7:00am EST

GLOBAL AEROSPACE CUSTOMER EXPANDS DEPLOYMENT OF VUZIX’ SAP-CERTIFIED WAREHOUSE SOLUTION 

Jan 25, 2023 8:15am EST

TELECOM CUSTOMER DEMAND FOR VUZIX SMART GLASSES RUNNING ON 4G AND 5G NETWORKS CONTINUES TO STEADILY EXPAND 

Jan 23, 2023 8:30am EST

OX COMMENCES DEPLOYMENT OF VUZIX SMART GLASSES AT ONE OF THE WORLD’S LARGEST LOGISTICS PLATFORM PROVIDERS 

Jan 17, 2023 8:30am EST

FORTUNE 50 GLOBAL RETAILER CONTINUES TO EXPAND ITS USE OF VUZIX SMART GLASSES TO SUPPORT ITS WAREHOUSING AND LOGISTICS OPERATIONS 

Jan 10, 2023 8:30am EST

VUZIX RECEIVES OEM PURCHASE ORDERS FROM MULTIPLE DEFENSE AND COMMERCIAL CUSTOMERS 

Jan 06, 2023 9:00am EST

VUZIX BLADE POWERS XANDER’S REAL-TIME CAPTIONING XANDERGLASSES FOR THE DEAF AND HARD OF HEARING

MANAGEMENT 

Paul J. Travers

PAUL J. TRAVERS

CEO, President and Director

Paul Travers is the founder of Vuzix and has served as our President and Chief Executive Officer since 1997 and as a member of our Board of Directors since November 1997. Prior to the formation of Vuzix, Mr. Travers founded both e-Tek Labs, Inc. and Forte Technologies Inc. He has been a driving force behind the development of our products. With more than 30 years’ experience in the consumer electronics field, and 26 years’ experience in the virtual reality and virtual display fields, he is a nationally recognized industry expert. He holds an Associate degree in engineering science from Canton, ATC and a Bachelor of Science degree in electrical and computer engineering from Clarkson University.

Grant Russell

GRANT RUSSELL

CFO, Executive Vice President, Treasurer and Director

Grant Russell has served as our Chief Financial Officer and Executive Vice President since 2000 and as a member of our Board of Directors since April 2009. From 1997 to 2004, Mr. Russell developed and subsequently sold a successful software firm and a new concept computer store and cyber café. In 1984, he co-founded Advanced Gravis Computer (Gravis), which, under his leadership as President, grew to become the world’s largest PC and Macintosh joystick manufacturer with sales of $44 million worldwide and 220 employees. Gravis was listed on NASDAQ and the Toronto Stock Exchange. In September 1996 it was acquired by a US-based Fortune 100 company via a successful public tender offer. Mr. Russell holds a Bachelor of Commerce degree in finance from the University of British Columbia and is both a US Certified Public Accountant and a Canadian Chartered Professional Accountant.

PETE JAMESON

COO

Pete Jameson was named Chief Operating Officer (COO) of Vuzix in January 2022, having served as General Manager since joining the company in January 2021. Mr. Jameson brings a wealth of operating experience to his new position. He previously served as COO of Osterhout Design Group (ODG), a leading wearable technology company that developed and manufactured mobile, self-contained and lightweight head-worn mixed reality smart glasses with photo-realistic imagery. Prior to ODG, Mr. Jameson was a 20-year executive at Eastman Kodak where he was a founding leader of Kodak’s multi-billion-dollar Digital Camera Business including General Manager and VP of the Digital SLR and Professional Digital Capture Group that created the world’s first digital SLR cameras, General Manager of Kodak’s Commercial Imaging Business in Europe, Africa and the Middle East and General Manager and VP of Kodak’s Digital Devices Group. He holds a Bachelor of Science Electrical Engineering degree from Union College and a Master of Business Administration degree from the University of Rochester Simon School of Business.

Eric Black

ERIC BLACK

General Counsel

Eric Black was named General Counsel of Vuzix in March 2022. Mr. Black brings a wealth of legal experience to his new position. While serving as in-house for other private and public technology companies, Mr. Black developed extensive experience in supporting business development and operational optimization by developing processes/workflows, negotiating complex contracts, advising on mergers and acquisitions, and informing business strategies that strengthen compliance and facilitate consistent growth. Mr. Black was previously named one of Rochester’s “Forty Under 40” by the Rochester Business Journal in 2006 and one of Rochester’s Top Counsel by the Rochester Daily Record in 2019. He holds a Bachelor of Economics degree from the University of Rochester and a Doctor of Jurisprudence degree from the University of Virginia School of Law.

SHANE PORZIO

Vice President Engineering

Shane Porzio has been with the Company for more than ten years and has more than 13 years of experience in architecture of systems and designs for hardware and software. His previous employment was at Lockheed Martin where he served as a Hardware Engineer. Mr. Porzio has BS in Computer Engineering Technology from Rochester Institute of Technology and his MS in Computer Science from Rochester Institute of Technology.

BILL BELTZ

Vice President of Global Sales

Bill Beltz brings a wealth of general management and sales experience to his new position. Prior to joining Vuzix, he served as Vice President of Sales at Snap One, a leading manufacturer and distributor of smart living technology. Prior to Snap One, he held sales and management positions of increasing responsibility at both NCR Corporation, a Fortune 500 software, consulting and technology company providing professional services and electronic products, and Radiant Systems, a provider of technology to the hospitality and retail industries that was subsequently acquired by NCR Corporation.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVENTEEN THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LEGENDS MEDIA  FOR A ONE DAY VUZI AWARENESS CAMPAIGN. WE HAVE PREVIOUSLY BEEN COMPENSATED THIRTY SEVEN THOUSAND FIVE HUNDRED USD IN TOTAL TO COVER VUZI. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

CTXR BRAND NEW PROFILE!

OUR NEW PROFILE IS:    NASDAQ: CTXR 

“MINO-WRAP” COULD REVOLUTIONIZE $400 MILLION POST-MASTECTOMY INFECTION PREVENTION MARKET

$41.7 MILLION IN CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2022

MINO-LOK® PHASE 3 TRIAL CLOSER TO COMPLETION WITH 169 PATIENTS RECRUITED, 72 FAILURE EVENTS AND 17 PATIENTS IN ACTIVE TREATMENT OR PENDING DATA REVIEW

DOWNLOAD THE INVESTOR PRESENTATION HERE

DOWNLOADS THE FACT SHEET HERE

_______________________________

Hello Everyone,

We have another exciting profile for Tuesday’s session.  This is a company that we have put on you’re radar several times and is up since we last covered it in March.  

Pull up CTXR Immediately.

There is no denying that 2023 has been a good year so far for CTXR.  The turnaround started back in late December after it hit low’s and it has been climbing slow and steady ever since.  Historically CTXR has made some big multi-week moves and the evidence is right on the chart.

Right now this one is trending green until something gets in it’s way.

They are a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a diversified pipeline of five active programs. Three of its pipeline candidates would be the first and only prescription treatments in their indications if approved by the FDA. The Company has two late-stage product candidates, Mino- Lok®, an antibiotic lock solution to salvage infected central venous catheters (CVCs) of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed its Phase 3 trial and is on track for submission of a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) in the second half of 2022. Mino-Lok® was granted Fast Track designation by the FDA. I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Citius has announced its intention to spinoff I/ONTAK into standalone oncology-focused publicly traded company. During the second quarter of 2022, Citius initiated a Phase 2b trial of Halo-Lido, potentially the first and only FDA-approved prescription treatment for hemorrhoids; patient enrollment in the trial is expected to be completed by the end of 2022. Citius has two additional pipeline assets in pre-clinical devleopment: a novel proprietary mesenchymal stem cell (i-MSC) treatment for acute respiratory conditions, and Mino-Wrap, for the prevention of infection in tissue expanders and breast implants post mastectomy.

There are several catalysts in play right now that we need to look at:

ANALYST TARGET:

Dawson James Analyst Jason Kolberts’ $10.00 target could mean potential upside of 1,198% for Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) right after bouncing off its 52-week low of $.77 cents on 12/30/22 according to Barchart.com’s price history.(32)(33)

ACTIVE CHART:

Since bottoming out and hitting its 52-week low of $.77 cents on 12/30/22, shares of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) have climbed to $1.13 for a solid 46.75% move in less than 10 days.(33)

FDA CONFIRMATION:

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has reported that the FDA confirmed Prescription Drug User Fee Act (PDUFA) target action date of July 28, 2023.(35)

PHASE 3 TRIAL:

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) completed Pivotal Phase 3 trial of I/ONTAK (E7777) and submitted biologics license application (BLA) to the U.S. Food and Drug Administration (FDA).(35)

BIOTECH CLUSTER WITH 70 NEW FDA APPROVALS:

The company is headquartered in a hotbed and breeding ground for successful Biotechs, which were responsible for a staggering 70 new FDA dr-ug approvals between 2020 and 2021.(40)

ACCELERATED ADVANCEMENT:

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) expanded and accelerated its Phase 3 Mino-Lok trial to additional sites outside the United States. If approved, Mino-Lok would be the first-and-only antibiotic lock solution FDA-approved to salvage infected central venous catheters (CVCs) causing catheter-related bloodstream infections (CRBSIs).(35)

CLINICAL COLLABORATION:

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) initiated a clinical collaboration with the University of Pittsburgh to evaluate regulatory T-cell (T-reg) depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid cancer tumors in a Phase 1 investigator-initiated trial, with first patient enrolled in November 2022.(37)

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Gets $10.00 Target From Dawson James Analyst Jason Kolberts.

Jason Kolberts is no stranger to the biotech and pharmaceutical industries.

He’s actually the Director of Research at Dawson James Securities, Inc.

And for those who don’t know, Dawson James is a full-service boutique investment banking firm focused on emerging growth companies since 2004 and committed to helping clients navigate the healthcare, biotechnology and technology markets. (38)

Jason Kolberts’ career began as a chemist in the pharmaceutical industry and evolved into a product and marketing manager with Schering-Plough in Japan. Upon returning from Japan, Jason joined Salomon Smith Barney, as a research associate which has now evolved into a 20-year career on Wall Street as a leader in the Healthcare space.(38)

Kolberts’ coverage expands across multiple therapeutic areas in biotechnology, specialty pharmaceuticals, and medical devices. As an analyst Jason has developed a high level of expertise in oncology, virology and cell-based medicine such as CAR (Chimeric Antigen Receptor)-T cells and regenerative medicine (stem cells).(38)

Prior to joining Dawson James, Mr. Kolbert spent the prior year as a senior biotechnology analyst at HC Wainwright and spent the previous seven years at the Maxim group, where he was an Executive Managing Director and the Head of Healthcare Research at the firm. During this period Jason and his team covered 80 names across the healthcare vertical. Jason’s Wall Street career began with seven years at Citi Group followed by several years on the buy side as a portfolio manager with the Susquehanna International Group.(38)

One company that seems to have caught the eye of Jason Kolbert is Citius Pharmaceuticals, Inc. (Nasdaq: CTXR).

Mr. Kolbert has a $10.00 target on Citius Pharmaceuticals, Inc. (Nasdaq: CTXR).(32)

This could mean a potential upside of 1,198% for Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) after a recent bounce off its 52-week low of $.77 cents on 12/30/22 according to Barchart.com’s price history.(33)

Listen. Nothing is certain. But look at the Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) weekly chart above and do a little technical analysis using StockCharts.com. You can see the following moving averages:(39)

Weekly average price is: $1.12 (as of 1/13/23)

50-day moving average at $1.18

200-day moving average at $1.28

20-day exponential moving average $1.07 (first line of resistance)

Shares of (CTXR) just trended above its first line of potential resistance at the $1.07 – $1.12 range(39). If (CTXR) is able to push through its 50-day moving average of $1.18… the next line of potential resistance could be its 200-day moving average at $1.28, which, if reached, would represent a potential 28% move as of 1/13/23’s opening price of $1.00.(38)(33) A move back to the 200-day moving average is not certain, but the potential should be noted.

How would that move be possible?

You see, shares of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) could be at the beginning of what’s called a “Descending Triangle Breakout Strategy.”(39)

…And by definition, the “Descending Triangle Breakout Strategy” as the name suggests, involves the anticipation of a breakout from the descending triangle pattern. (41)

The basic premise of using this strategy is to look at volume once you’ve identified the pattern. You can typically observe that volume begins to diminish toward the end of the descending triangle pattern formation. (41)

After bottoming out and hitting its 52-week low of $.77 cents on 12/30/22, shares of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) have climbed to $1.13 for a solid 46.75% move in less than 10 days.(33)

Could this be the beginning of a much larger move?

Shares of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) would need to climb over 1,198% to reach the $10.00 target set by Dawson James Analyst, Jason Kolberts, from that 52-week low.(32)

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Has Built a Diversified Pipeline of Therapeutics with a Multi-Billion-Dollar Total Addressable Market.(43)

Non-Hodgkin’s Lymphoma is one of the deadliest forms of cancer. 

Targeting your body’s germ-fighting immune system, it invades your body’s lymph nodes. Left unchecked, it can kill more than 1-in-3 of those diagnosed, with over a half-million new cases each year.

But one company could be set to change all that…

Flying well under the radar, Citius Pharmaceuticals (NSDQ: CTXR) has quietly acquired the rights to the experimental compound “E-7777,” (27) a direct improvement to a previously FDA-approved medication that directly attacks infected cancer cells inside the human body.

And this new cancer-fighting remedy could be mere months away from its own approval. If and when it hits the market, this new treatment could provide a whole new proven alternative to the harsh side effects of chemotherapy or aggressive radiation treatment.

Directly targeting and attacking infected cells, E-7777 could transform the $5.4 Billion market for Non-Hodgkin’s Lymphoma treatment.

The best part of this whole story? This is just one of several potentially game-changing new therapies in the company’s pipeline …

CITIUS PHARMACEUTICALS, INC. IS A BIOPHARMA POWERHOUSE HIDING IN PLAIN SIGHT

Citius Pharmaceuticals United States NASDAQ: (CTXR) is what’s called a “late-stage biopharmaceutical” company, where a highly-experienced management team purchases rights to the most promising new therapies and then either brings them to market or licenses rights to bigger pharma companies like Pfizer or Johnson & Johnson.

It should go without saying that “late-stage” development is the most difficult, most expensive part of the process for any new kind of treatment. Because even after years of investment, research and development, some 2 out of 5 drugs still fail to secure final FDA approval.(30)

But with a “Dream Team” of top industry insiders, Citius is turning the odds in their favor—with two treatments now in Phase 3, and both looking like they will pass.

In addition to E-7777, it’s currently advancing three proprietary product candidates in total:(12)

• Mino-Lok has advanced to Phase 3 clinical studies.
• CITI-101 (Mino-Wrap) is a malleable, bio-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies.
• CITI-002 is being developed to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids.

We’re going to focus primarily on Mino-Lok here, since it’s Citius Pharmaceuticals’ most promising (and most immediate) potential revenue source …

Source 13

MINO-LOK’S PHASE 3 CLEARANCE COULD BE THE KEY TO COMMANDING A $1.5 BILLION 2 MARKET:

Mino-Lok is an antibiotic designed to treat patients with catheter-related bloodstream infections (CRBSIs). At present, these infections are treated by removing the catheter and prescribing antibiotics.

This is a costly medical process with potential complications. In fact, studies show that removal and reinsertion of CVCs have a 15% to 20% complication rate, including pneumothorax, misplacement, and arterial puncture. (4)

Mino-Lok allows doctors to treat the infection without needing to remove the catheter, avoiding both costs and complications.

North America is projected to account for a major share of the global catheter-related bloodstream infections market during the forecast period due to well-established health care infrastructure. Europe is anticipated to be the second largest market from 2020 to 2030. (31)

This market has very little, if any, competition

But here’s the biggest catalyst for Citrus, the global catheter-related bloodstream infections market is highly consolidated due to the presence of a small number of key players – which means at this time there is very little in the way of competition. (31)

Currently, in Phase 3 pivotal trials, it could be approved in a matter of months … giving Citrus a massive leg up on any competition.

According to CEO Myron Holubiak: (14)

“Data from the Mino-Lok® (M-L) Phase 3 program was reviewed by our independent Data Monitoring Committee (DMC) for safety and efficacy and found to be progressing as planned with no recommended changes to trial design.”

MINO-LOK HAS REPORTEDLY PERFORMED WELL TO DATE: (18)

• Mino-Lok is the first and only therapy under investigation to salvage infected CVCs. In a Phase 2b trial, the Mino-Lok product demonstrated a 100% efficacy rate in salvaging colonized CVCs.
• Mino-Lok had no significant adverse events compared to an 18% serious adverse event rate when infected CVCs were removed and replaced.
• FDA Fast Track with QIDP designation and patent protection until June 2024. Formulation patent protection until November 2036. Currently in a Phase 3 pivotal superiority trial. (14)

MEANWHILE, CITIUS’ “MINO-WRAP” COULD REVOLUTIONIZE $400 MILLION
POST-MASTECTOMY INFECTION PREVENTION MARKET

Citius’ Mino-Wrap could help reduce post-operative infections associated with surgical implants. Its gel-containing film is used primarily to wrap the tissue expander used in breast reconstructive surgeries.

As also noted by CEO Holubiak: (14)

“We believe that this serious condition impacts about 100,000 women in the U.S. and many more in the rest of the world. Mino-Wrap is a bio-absorbable, antimicrobial semi-solid film that is wrapped around a tissue expander and placed in the surgical pocket following a mastectomy to prevent post-surgical infections. Once implanted, Mino-Wrap slowly dissolves in situ for a specified period of time, providing extended protection against infection.”

PROGRAM HIGHLIGHTS (19)

• Potential to be first and only FDA-approved product to prevent infections associated with post-mastectomy breast implants
• Currently in preclinical development
• Development in partnership with The University of Texas MD Anderson Cancer Center and support from medical thought leaders

Get Instant Access to Investor Materials 

OFFERING RELIEF IN AN $80 MILLION HEMORRHOIDS MARKET

Shockingly, there are no FDA-approved prescription products for hemorrhoids at the moment.(16)

However, that could soon change with Citius’ halobetasol and lidocaine formulations.

Hemorrhoids are an uncomfortable and often recurring condition. However, despite the numerous prescriptions and over the counter (OTC) products commonly used to treat hemorrhoids, none possess the necessary safety and efficacy data generated from rigorously conducted clinical trials.

Citius believes its halobetasol-lidocaine product could one day become that go-to treatment for physicians wanting to provide patients with a therapy demonstrating safety and efficacy.(16)

PROGRAM HIGHLIGHTS: (20)

• There are no FDA-approved prescription products on the market for hemorrhoids
• Citius’ halobetasol and lidocaine formulation could become the first FDA-approved prescription product to treat hemorrhoids in the United States
• According to IMS, over 25 million units of topical combination prescription products for hemorrhoids are sold in the US

CITIUS PHARMACEUTICALS COULD EVEN HELP TREAT ARDS, TOO

• There are about three million cases of Acute Respiratory Distress Syndrome (ARDS) globally, with approximately 200,000 instances just in the U.S.(17)
• The health crisis significantly added to the amount of ARDS cases, with death rates among patients on ventilators as high as 50%.(17)

• Worse, at the moment, there are no approved treatments for ARDS.(17)

According to Citius CEO Holubiak:

“Currently, there is no FDA-approved drug therapy for ARDS. We plan to submit an IND to the FDA and initiate our Phase 1 study by the end of the second quarter of 2022. Our first-in-human clinical trial is entitled “i-MSCs in Subjects with Acute Respiratory Distress Syndrome (ARDS) Due to [the health predicament]: i-MARCO.” Following the completion of a multi-center Phase 1 pilot study, we would expect to proceed on to a double-blinded, randomized Phase 2/3 trial to demonstrate the safety, efficacy, and multimodal healing capabilities of our i-MSCs in patients with moderate to severe ARDS due to [the health predicament].” (14)

PROGRAM HIGHLIGHTS: (21)

• Novel stem cell therapy for the treatment of acute inflammatory respiratory disorders including acute respiratory distress syndrome (ARDS)
• i-MSCs derived from induced pluripotent stem cell reprogrammed using proprietary mRNA process
• No FDA-approved treatment for ARDS exists today
• Preclinical activities are underway

Get Instant Access to Investor Materials 

$7.2 BILLION IN POTENTIAL MARKET DISRUPTION

As you’ve seen today, some of the treatments in Citius Pharmaceuticals’ portfolio go far beyond the definition of “Cutting Edge” …

Mino-Lock could potentially erase the need to operate on those suffering from Catheter-Related Bloodstream Infections (CRBIs), revolutionizing treatment of a $1.5 Billion medical problem overnight. E-7777 could offer a powerful new alternative to those suffering from Non-Hodgkin’s Lymphoma.

Combined with a full pipeline of other treatments, Citius Pharmaceuticals could be sitting on top of $5.5 Billion in cumulative pharmaceutical market disruption…

With a full year’s “cash runway” (through December 2023)(43)left to complete critical Research & Development, along with the outrageous profit potential if even one of these treatments makes it to market, Citius Pharmaceuticals (NSDQ:CTXR) is a company that should definitely be on your radar.

CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR) IS HEADQUARTERED IN ONE OF THE COUNTRY’S HOTTEST BREEDING GROUNDS FOR FOR SUCCESSFUL BIOTECH’S

“This was the first year that Citius qualified for the program, and we are delighted to have been selected to participate in New Jersey’s NOL Program. As a pre-revenue business, this program allows us to convert certain losses from operations into tangible working capital today, supporting our ongoing research and development efforts. We are thankful to the NJ Economic Development Authority for aiding our efforts in our initial year of participation. This non-dilutive funding will provide added cash runway as we advance a late-Phase 3 trial for Mino-Lok®, a Phase 2b trial for Halo-Lido, and a recently submitted biologics license application (BLA) for I/ONTAK,” stated Jaime Bartushak, Chief Financial Officer of Citius.(45)

New Jersey’s biotechnology cluster has grown from a mere 30 companies in the early 1990s to approximately 3,200 establishments in the state today. 46 of those firms are responsible for a staggering 70 new FDA drug approvals between 2020 and 2021, according to the trade association BioNJ.(40)

And several sources indicate that despite recent IPO and capital market challenges, the biotech cluster’s ascension continues.(40)

Debbie Hart, president and CEO of BioNJ, says of the overall US/global biotech community: “The science is advancing by leaps and bounds, and it’s creating lots of opportunities, new companies, and new advances in therapies and treatments.”(40)

“When you look at what happened during the global pandemic – how the industry can really save the world – [it’s] not an understatement. It just speaks to ability and the science.”(40) 

New Jersey’s specific biotech juggernaut partly stems from a constellation of cutting-edge advances in cell and gene therapy operating in tandem with a Garden State life sciences ecosystem replete with contract manufacturing and clinical research organizations, as well as specialized accountants, attorneys, and other professionals who serve the industry.(40)

Such a network is particularly important for the biotechnology community given the challenges it faces.(40)

Dean J. Paranicas, president and CEO of the HealthCare Institute of New Jersey (HINJ), details the overall “high-risk profile” for the biopharmaceutical industry: “There’s that challenge of having enough capital to develop your product, being able to get it through the regulatory cycle, and then commercializing [it] and getting it into the marketplace.”(40)

Paranicas additionally explains that New Jersey firms have beneficial opportunities to coordinate with the state’s research institutions as well as with more established companies located here.(40)

Also helping to lubricate the state’s growing industry is New Jersey’s proximity to Wall Street and, separately, a time-zone advantage, which facilitates business communication with locales as diverse as, say, California and the United Kingdom.(40)

In November of 2022, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced it had secured $3.6 million through New Jersey Economic Development Program.(45)

CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR) ANNOUNCES A CLINICAL COLLABORATION WITH THE UNIVERSITY OF PITTSBURGH.(46)

Source 47

The study consists of two parts. Part I is a dose escalation study of four cohorts (3,6,9,12 mcg of I/ONTAK) and is expected to enroll 18-30 patients. Part II is a dose expansion study of approximately 40 patients to evaluate the safety and tolerability of the recommended combination dose of I/ONTAK and pembrolizumab.(46)

The study will also investigate the alteration of the immune microenvironment within tumors and peripheral blood. Secondary endpoints include the objective response (complete response plus partial response), progression-free survival, and overall survival.

I/ONTAK is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. I/ONTAK, a purified version of denileukin diftitox, is a reformulation of previously FDA-approved oncology treatment ONTAK.

ONTAK was marketed in the U.S. from 1999 to 2014, when it was voluntarily withdrawn from the market. Manufacturing improvements resulted in a new formulation, which maintains the same amino acid sequence but features improved purity and bioactivity. The new formulation received regulatory approval in Japan in 2021 for the treatment of CTCL and PTCL. In 2011 and 2013, the FDA granted orphan drug designation (ODD) to I/ONTAK for the treatment of PTCL and CTCL, respectively.(46)

Source 48

In September of 2022, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced a collaboration with Dr. Haider Mahdi at the University of Pittsburgh in an investigator-initiated trial to evaluate I/ONTAK (“denileukin diftitox” or “E7777”) in combination with pembrolizumab in the treatment of recurrent or metastatic solid tumors.

“We are honored to support Dr. Mahdi and his team at the University of Pittsburgh in this Phase 1 investigator-initiated study to evaluate I/ONTAK as a combination therapy in the treatment of solid tumors. This study will expand the body of knowledge about I/ONTAK’s unique mechanism-of-action targeting the CD25 component of the IL-2 receptor which is present on both malignant T-cells (T-cell leukemias and lymphomas) and immunosuppressive regulatory T-cells (T-regs),” stated Dr. Myron Czuczman, Chief Medical Officer of Citius.

“Preclinical research in a syngeneic solid tumor mouse model shows that E7777 (denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 therapy. This data provides a positive signal of denileukin diftitox’s potential in the immuno-oncology space. There remains a significant ongoing need for innovative, effective, and well-tolerated treatments for cancer patients with solid tumors, and we are excited that I/ONTAK may provide meaningful antitumor activity in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®),” added Dr. Czuczman.(46)

Additionally, Citius is collaborating with an investigator-initiated study at the University of Minnesota (UMN). This Phase 1 dose-finding study to evaluate I/ONTAK prior to tisagenleucel (KYMRIAH®) CAR-T therapy in patients with diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.

The investigator-initiated trial at UPMC is an open label, Phase I/Ib study to evaluate T-reg cell depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid tumors.

“Encouraging clinical data emerging in the field of tumor immunotherapy have demonstrated that therapies focused on enhancing T-cell responses against cancer result in a significant survival benefit in patients with advanced malignancies. Overexpression of PD-L1 on tumor cells has been reported to impede anti-tumor immunity, resulting in immune evasion. The interruption of the PD-1:PD-L1 pathway combined with diminishing the suppressive effect by T-regs may represent an attractive strategy for restoring tumor-specific T-cell immunity. This first in human I/ONTAK plus anti-PD-1 combination immunotherapy study is a significant step towards advancing a T-cell-based therapeutic approach to treating solid tumors,” stated Dr. Haider Mahdi, University of Pittsburgh, Assistant Professor, Department of Obstetrics, Gynecology & Reproductive Sciences. Education & Training.(46)

Additionally, Citius is collaborating with an investigator-initiated study at the University of Minnesota (UMN). This Phase 1 dose-finding study to evaluate I/ONTAK prior to tisagenleucel (KYMRIAH®) CAR-T therapy in patients with diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.

The investigator-initiated trial at UPMC is an open label, Phase I/Ib study to evaluate T-reg cell depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid tumors.

CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR) REPORTS FISCAL FULL YEAR 2022 FINANCIAL RESULTS, PROVIDES BUSINESS UPDATE, ENDING THE YEAR WITH OVER $41 MILLION IN CASH.(35)

Source 49
  • $41.7 million in cash and cash equivalents as of September 30, 2022; extends runway through December 2023.
  • Mino-Lok® Phase 3 trial closer to completion with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review.
  • I/ONTAK BLA accepted for filing by the FDA; updated PDUFA target action date is July 28, 2023.
  • Halo-Lido Phase 2b trial progressed; data readout expected 2H 2023.
  • Multiple value-driving catalysts anticipated in 2023, including a potential drug approval and two trial completions.

On December 22, 2022 Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)reported business and financial results for the fiscal full year ended September 30, 2022.

Fiscal Full Year 2022 Business Highlights and Subsequent Developments Completed Pivotal Phase 3 trial of I/ONTAK (E7777) and submitted biologics license application (BLA) to the U.S. Food and Drug Administration (FDA).

FDA confirmed Prescription Drug User Fee Act (PDUFA) target action date of July 28, 2023.

Advanced Mino-Lok® Phase 3 trial.

Initiated Phase 2b trial of Halo-Lido for the treatment of hemorrhoids in April 2022; patient enrollment ongoing with data readout expected 2H 2023.

Initiated clinical collaboration with the University of Pittsburgh to evaluate regulatory T-cell (T-reg) depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid cancer tumors in a Phase 1 investigator-initiated trial, with first patient enrolled in November 2022.

Approved for $3.6 million in non-dilutive capital through the New Jersey Economic Development Program to support ongoing research and development efforts.

“In 2022, we focused on execution across our key development programs: I/ONTAK, Mino-Lok and Halo-Lido. These efforts, combined with a prudent use of funds, enabled us to meaningfully advance our pipeline. We believe we have sufficient runway through December 2023 to realize additional value-creating milestones, including a potential FDA approval and two anticipated trial completions in the coming calendar year,” stated Leonard Mazur, Chairman and CEO of Citius.(35)

“Our Phase 3 Mino-Lok trial is now significantly closer to completion. While we expected to achieve 92 catheter failure events with 144 patients by the end of 2022, the trial’s observed catheter failure event rate has proven to be lower than anticipated. Consequently, we must continue recruiting patients. By successfully re-engaging with our U.S. trial sites as they recovered from the impact of CVD, we were able to drive patient recruitment. We have now exceeded our targeted enrollment and have achieved 72 of the required catheter failure events, with additional patients under review. To augment our recruitment efforts and continue the positive momentum in enrollment, we expanded the Mino-Lok trial to include sites in India. Once all new trial sites are fully activated, we will have nearly doubled our clinical site footprint. With these additional sites helping to drive incremental enrollment, we anticipate that the 92-event threshold required to complete the trial is achievable in the coming months,” added Mazur.(35)

“During the year, we also completed a Phase 3 trial and submitted a BLA for I/ONTAK, an oncology asset we in-licensed just over a year ago. Upon further discussion with the FDA, the PDUFA target date has been set for July 28, 2023…

We remain committed to establishing a robust commercial infrastructure to support I/ONTAK’s successful product launch, if approved. In the second half of 2022, we also extended our support for a Phase 1 investigator-initiated study of I/ONTAK in combination with pembrolizumab (Keytruda®1) to treat patients with recurrent or metastatic solid tumors…

This study has begun recruiting patients and is the second investigator-initiated trial to explore I/ONTAK’s potential as a combination therapy in much larger immuno-oncology markets…

We continue to believe I/ONTAK’s value extends beyond a potential initial indication in persistent or recurrent cutaneous T-cell lymphoma. Earlier in the year, we announced our intention to spin off I/ONTAK. Given broader market conditions, we continue to evaluate opportunities to further unlock this asset’s value,” continued Mazur.(35)

“In addition to advancing our Phase 3 trials, we initiated a Phase 2b trial for Halo-Lido, our prescription strength topical formulation for hemorrhoids. The trial began enrolling patients with symptomatic Grade II or III hemorrhoids in the second quarter of 2022. Recent recruitment has accelerated and we expect complete trial data available in the second half of 2023,” added Mazur.

“As financial stewards, we continuously evaluate the optimal capital structure for the company. We believe our anticipated catalysts, along with a healthy cash position, provide us with several strategic and financial options with which to continue advancing our pipeline…

This may include the previously announced potential spinoff of I/ONTAK into a standalone oncology company, pending market conditions, and other standalone financing alternatives available to us. We are encouraged by the multiple value-driving catalysts anticipated in calendar 2023, including a potential drug approval and two trial completions, and look forward to extending our positive momentum in the months ahead,” concluded Mazur.(35)

NEWS

01/11/2023

Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

12/22/2022

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update

12/01/2022

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

11/21/2022

Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program

11/09/2022

Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting

10/18/2022

Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022

10/06/2022

Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022

09/28/2022

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

09/22/2022

Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial

09/15/2022

Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute

09/08/2022

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

09/07/2022

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

08/11/2022

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update

07/12/2022

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma

05/25/2022

Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company

05/18/2022

Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022

05/12/2022

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update

05/06/2022

Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally

05/03/2022

Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones

04/26/2022

Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

04/14/2022

Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022

04/13/2022

Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates

MANAGEMENT

LEONARD MAZUREXECUTIVE CHAIRMAN, DIRECTOR

Portrait

Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding and building multiple healthcare companies, and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is also the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC, a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From 2005 to 2012, Mr. Mazur co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC, a specialty pharmaceutical company producing prescription dermatological drugs. Earlier, he was the founder and Chief Executive Officer of Genesis Pharmaceuticals, Inc., a dermatological products company that marketed its products through dermatologists’ offices and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and business development experience from previous tenures at Medicis Pharmaceutical Corporation, ICN Pharmaceuticals, Inc., Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.

Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and served in the U.S. Marine Corps Reserves.

MYRON HOLUBIAKPRESIDENT AND CHIEF EXECUTIVE OFFICER, DIRECTOR

Portrait

Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. From 1998 to 2001, Mr. Holubiak served as President of Roche Laboratories, Inc., a premier multinational research-based pharmaceutical company. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. During his 19-year tenure at Roche Labs, Mr. Holubiak also held multiple sales and marketing roles. Prior to Roche, Mr. Holubiak founded Emron, Inc., a health economics and managed care consulting company, and helped establish the Academy of Managed Care Pharmacy (AMCP). From 2012 to 2016, Mr. Holubiak served as Chairman of the Board of Bioscrip, Inc., a national home infusion company. Since 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. and its predecessor, Ventrus Biosciences, Inc., and is a trustee of the Academy of Managed Care Pharmacy Foundation.

Mr. Holubiak received a BS in molecular biology and biophysics from the University of Pittsburgh. He received advanced business training from Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.

JAIME BARTUSHAKCHIEF FINANCIAL OFFICER

Portrait

Mr. Bartushak is an experienced finance and operations professional for early-stage pharmaceutical companies, and has over 20 years of corporate finance, business development, M&A, restructuring, capital formation, and strategic planning expertise. Mr. Bartushak is a founder of Leonard-Meron Biosciences, and, as CFO, was instrumental in obtaining initial investment capital for its start-up in 2014. Earlier, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc., and before that, he led the financial efforts for the successful sale of Triax Pharmaceuticals to PreCision Dermatology.

Mr. Bartushak holds a Master of Science and BS from the New Jersey Institute of Technology.

MYRON S. CZUCZMAN, MDCHIEF MEDICAL OFFICER AND EVP

Portrait

Dr. Czuczman is an experienced physician-scientist, academic oncologist, and pharma executive with decades of experience in strategic design, implementation, and oversight for the global development of novel therapeutics for hematologic malignancies. Dr. Czuczman joined Citius from Celgene where he was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL. In this role, Dr. Czuczman managed a global team of physicians and scientists responsible for cross-functional development of compounds from proof-of-principle to worldwide registration. Prior to his career in pharma, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI-designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Roswell Park Comprehensive Cancer Center.

Dr. Czuczman received his medical degree from the Pennsylvania State University College of Medicine after graduating magna cum laude in biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center in New York City.

GARY F. TALARICOEVP, OPERATIONS

Portrait

Mr. Talarico has served as EVP, Operations since March 2016. Mr. Talarico has successfully built and led all commercial activities for a number of start-up companies. Most recently, he was a founder, partner and Executive Vice President of Leonard-Meron Biosciences, Inc.; he was instrumental in acquiring its lead product. Previously, Mr. Talarico served as Senior Vice President of Triax Pharmaceuticals, from its founding to the sale of its assets. Mr. Talarico was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Before Reliant, he was Executive Vice President of Business Development for Ventiv Health. His earlier experience included tenures as Vice President of Sales for Medicis Pharmaceutical Corporation at its start-up, and Director of Sales at ICN Pharmaceuticals, Inc. Mr. Talarico is a graduate of Lewis University.

JAY WADEKARSVP, BUSINESS STRATEGY

Portrait

Mr. Wadekar has been associated with Citius since its inception. Prior to Citius, he lead the clinical program at Ischemix, Inc., a company developing novel therapies for cardiovascular conditions. Mr. Wadekar has more than thirty years of experience in areas of finance, corporate strategy, sales and senior leadership in the healthcare field. Mr. Wadekar has held numerous executive level positions throughout his career in biotechnology and pharmaceutical industries including Chairman and CEO of Able Laboratories, Inc. Most recently he served as a strategic advisor to Camber Pharmaceuticals, Inc. where he was instrumental in building the executive team and establishing Camber’s Sales Operations systems.

ALAN LADER, PHDVP, CLINICAL OPERATIONS

Portrait

Dr. Lader has served as VP, Clinical Operations since March 2016. Dr. Lader has over 25 years of experience in medical research. Prior to joining Citius, Dr. Lader was the Director of Clinical Operations for Ischemix, Inc. Dr. Lader was an Instructor in Medicine at Harvard Medical School and Brigham and Women’s Hospital, where he taught Integrated Human Physiology, and was Principal Investigator for NIH-funded studies in mechanisms of lung cancer metastasis. Dr. Lader has authored over 20 publications in peer-reviewed journals, and has presented more than 20 abstracts at scientific meetings. He received his PhD from the University of South Carolina School of Medicine. He received an MS degree from Rensselaer Polytechnic Institute in Biomedical Engineering and a BS degree in Bioengineering from Syracuse University.

ILANIT ALLENVP, INVESTOR RELATIONS

Portrait

Ms. Allen has more than 20 years of experience in corporate communications, investor relations, strategy and investment banking. Since 2014, Ms. Allen has provided investor relations counsel to more than two dozen private and public life science companies. Previously, she advised executives across a broad spectrum of industries and growth stages, including technology startups and Fortune 500 financial institutions. Ilanit began her career as an investment banking analyst at SG Cowen with a focus on mergers and acquisitions. Ms. Allen holds an MBA from Harvard Business School, a Bachelor of Science degree in Finance from The Wharton School, and a Bachelor of Arts degree in International Relations from the University of Pennsylvania.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVENTEEN THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LEGENDS MEDIA  FOR A ONE DAY CTXR AWARENESS CAMPAIGN. WE HAVE PREVIOUSLY BEEN COMPENSATED THIRTY SEVEN THOUSAND FIVE HUNDRED USD IN TOTAL TO COVER CTXR. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

SOURCE LIST

Source 2: https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-highlight-its-phase-3-clinical-trial-product-mino-lok-at-benzinga-biotech-small-cap-conference-on-march-25-301253709.html

Source 3: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093967/

Source 4: https://www.citiuspharma.com/opportunity/crbsis/

Source 5: https://www.everydayhealth.com/things-your-doctor-wont-tell-about-hospital-infections/

Source 6: https://www.gurufocus.com/news/697235/citius-announces-united-states-patent-trademark-office-registered-the-companys-minolok-trademark

Source 7: https://www.citiuspharma.com/mino-lok/

Source 8: https://www.citiuspharma.com/wp-content/uploads/2021/02/CTXR_Shareholder_Letter_Feb2021.pdf

Source 9: https://www.citiuspharma.com/mino-wrap/

Source 10: https://stockcharts.com/h-sc/ui?s=ctxr

Source 11: https://www.barchart.com/stocks/quotes/CTXR/opinion

Source 12: https://www.citiuspharma.com

Source 13:https://d1io3yog0oux5.cloudfront.net/_335875ea4142d81b5406df99d97e4cdf/citiuspharma/db/249/1064/pdf/3.19.2021.WEB.Presentation_Final.pdf

Source 14: https://www.citiuspharma.com/wp-content/uploads/2021/02/CTXR_Shareholder_Letter_Feb2021.pdf

Source 15: https://www.citiuspharma.com/mino-wrap/

Source 16: https://www.citiuspharma.com/halo-lido/

Source 17: https://ir.citiuspharma.com/press-releases/detail/122/citius-pharmaceuticals-signs-an-exclusive-worldwide

Source 18: https://citiuspharma.com/pipeline/mino-lok/default.aspx

Source 19: https://citiuspharma.com/pipeline/mino-wrap/default.aspx

Source 20: https://www.citiuspharma.com/halo-lido/#:~:text=There%20are%20no%20FDA%2Dapproved,hemorrhoids%20in%20the%20United%20States

Source 21: https://citiuspharma.com/pipeline/stem-cell-platform/default.aspx

Source 22: https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/statistics#:~:text=The%20overall%205%2Dyear%20survival,survival%20rate%20is%20around%2063%25.

Source 23: https://pubmed.ncbi.nlm.nih.gov/30895415/

Source 24: https://www.nuventra.com/resources/blog/why-do-clinical-trials-fail/#:~:text=This%20means%20that%20around%202,3%20fail%20to%20reach%20approval.

Source 25: https://www.google.com/search?rlz=1C1CHBF_enUS977US977&q=NASDAQ:+CTXR&stick=H4sIAAAAAAAAAONgecRowS3w8sc9YSn9SWtOXmPU5OIKzsgvd80rySypFJLmYoOyBKX4uXj10_UNDZOSzSxLDLIzeBax8vg5Brs4BlopOIdEBAEAzts1gUwAAAA&sa=X&ved=2ahUKEwi9i77gz8r0AhV1SzABHY-TBrkQsRV6BAg0EAM&biw=1536&bih=792&dpr=1.25

Source 26: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctxr/citius-pharmaceuticals/news/we-think-citius-pharmaceuticals-nasdaqctxr-can-afford-to-dri-1

Source 27: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctxr/citius-pharmaceuticals#intrinsic-value

Source 28: https://github.com/SimplyWallSt/Company-Analysis-Model/blob/master/MODEL.markdown#value

Source 29: https://finance.yahoo.com/quote/CTXR/history?p=CTXR

Source 30: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609997/

Source 31: https://www.biospace.com/article/catheter-related-bloodstream-infections-market-rise-in-prevalence-of-bloodstream-infection-is-projected-to-drive-the-global-market

Source 32 : https://dawsonjames.com/wp-content/uploads/2022/12/CTXR.12.23.22_-final1.pdf

Source 33 : https://www.barchart.com/stocks/quotes/CTXR/price-history/historical

Source 34 : https://finance.yahoo.com/news/citius-pharmaceuticals-inc-announces-u-123000919.html

Source 35 : https://finance.yahoo.com/news/citius-pharmaceuticals-inc-reports-fiscal-213000115.html

Source 36 : https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-accelerate-phase-3-mino-lok-trial-by-expanding-trial-sites-internationally-301541596.html

Source 37 : https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-a-clinical-collaboration-with-the-university-of-pittsburgh-to-evaluate-t-reg-cell-depletion-with-iontak-e7777-in-combination-with-pembrolizumab-in-recurrent-or-metastatic-solid-cancer-tumors-in–301631592.html

Source 38 : https://dawsonjames.com/wp-content/uploads/2019/06/KolbertDORPRFinal.pdf

Source 39 : https://schrts.co/fUAydCuY

Source 40 : https://njbmagazine.com/monthly-articles/njs-burgeoning-biotech-industry/

Source 41 : https://www.thebalancemoney.com/triangle-chart-patterns-and-day-trading-strategies-4111224

Source 42 : https://mma.prnewswire.com/media/1593817/Citius_Logo.jpg?p=facebook

Source 43 : https://s28.q4cdn.com/169506891/files/doc_presentation/2022/12/Corporate-Overview-December-2022-FINAL.pdf

Source 44 : https://www.marketwatch.com/investing/stock/ctxr?mod=search_symbol

Source 45 : https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-secures-3-6-million-through-new-jersey-economic-development-program-301683193.html

Source 46 : https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-a-clinical-collaboration-with-the-university-of-pittsburgh-to-evaluate-t-reg-cell-depletion-with-iontak-e7777-in-combination-with-pembrolizumab-in-recurrent-or-metastatic-solid-cancer-tumors-in–301631592.html

Source 47 : https://www.pitt.edu/sites/default/files/styles/tier_one_hero/public/2021-07/mission-t1-cl-top-aerial.jpg?h=2c66ef4f&itok=YlGwAwOr

Source 48 : https://pbs.twimg.com/media/FmDiCOXXEAEcTfc?format=jpg&name=large

Source 49: https://www.adva.com/-/media/adva-main-site/about-us/investors/financial-results/financial-statements/financial-statements.jpg?rev=c7ba9b4d5faa4f73aecf63165df2b1a2

Source 50: https://citiuspharma.com/about/management-team/default.aspx

Categories
Report

(NASDAQ: GNPX) Brand NEW Profile

OUR NEW PROFILE IS:   (NASDAQ: GNPX)

________________________

GNPX HAS ALREADY RECEIVED FAST TRACK DESIGNATION FOR ACCLAIM 2

GENPREX ANNOUNCES U.S. PATENT FOR REQORSA™ IMMUNOGENE THERAPY IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCERS

INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM IN NON-SMALL CELL LUNG CANCER AT THE 2023 AACR ANNUAL MEETING

CHECK OUT THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

Our profile from Monday just hit .85, up 24% off the average trade and 45% off of the lows on the session.  Yesterday it pulled back before exploding all the way to .85 today on strong interest.  Congrats if you watched that one.

We have another exciting profile for tomorrow’s session that is picking up momentum this week and they just released two strong pieces of news.

Pull up GNPX right away.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

Rodney Varner, CEO of Austin-based biotech company Genprex, stands at the podium during the closing bell ceremony for the Nasdaq exchange in 2018 following the company's initial public offering of stock. [Photo courtesy Genprex]

Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans.

ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body.

The Company’s lead product candidate, REQORSA™ is being evaluated as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer.

Genprex’s diabetes gene therapy approach consists of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas.

In models of Type 1 diabetes, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

In Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished.

Research And Development Pipeline

GNPX Email Image 1.0

CATALYSTS

– Addressing unmet medical need in large markets through the buildout of a robust pipeline of new drug candidates and drug combinations.

– Leveraging a gene therapy platform; Genprex’s non-viral ONCOPREX® Nanoparticle Delivery System is designed to deliver a variety of therapeutic genes to fight multiple types of cancer.

– REQORSATM immunogene therapy, the first systemically delivered gene therapy used for cancer in humans, can be combined with top-selling cancer drugs and may improve their benefits.

– Genprex has demonstrated clinical achievement with REQORSA in two clinical trials, showing a favorable safety profile and evidence of efficacy in lung cancer.

– GPX-002, Genprex’s diabetes gene therapy, works to transform alpha cells in the pancreas into insulin producing beta-like cells. A Phase 1 clinical trial could be the first-ever gene therapy tested in humans for diabetes.

– Advancing novel gene therapies in diseases with large markets and unmet needs.

– Two NSCLC trials currently enrolling; both with FDA Fast Track Designations.

– World class academic partners.

 

CLINICAL TRIALS

ONC-001

EVALUATING THE SAFETY OF REQORSA® IMMUNOGENE THERAPY AS A MONOTHERAPY (COMPLETED)

A Phase 1 dose escalation trial was conducted at The University of Texas MD Anderson Cancer Center evaluating the systemic, intravenous delivery of REQORSA® (TUSC2/FUS1) as a monotherapy in stage IV recurrent, metastatic lung cancer patients. The primary objective of this Phase 1 trial was to assess the toxicity of REQORSA administered systemically and intravenously, to determine the maximum tolerated dose, or MTD, and to determine a recommended Phase 2 dose of REQORSA alone.

THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS

The study showed for the first time that a tumor suppressor gene can be delivered systemically, intravenously and selectively to a patient’s cancer cells using a systemic nanoparticle vector. Although this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in a number of patients. REQORSA was well tolerated with tumor responses noted in lung primary and metastatic cancers in the liver, pancreas, and lymph nodes. In addition, pre- and post-treatment patient biopsies demonstrated that intravenous REQORSA selectively and preferentially targeted patients’ cancer cells.

Metabolic Tumor Response in a Metastatic Lung Cancer Subject

This subject survived after subsequent therapy more than seven years after the final treatment with REQORSA, to our knowledge, without evidence of cancer progression in the responding sites.

ONC-002

COMBINING REQORSA® IMMUNOGENE THERAPY WITH TARCEVA (ERLOTINIB)

PHASE 1 PORTION COMPLETED; PHASE 2 PORTION NO LONGER ENROLLING DUE TO OUR CHANGE OF FOCUS TO CONDUCT ACCLAIM-1

A Phase 1/2 clinical trial evaluated REQORSA® in combination with Tarceva® in stage IIIB/IV lung cancer patients without an activating EGFR mutation and in patients with an activating EGFR mutation whose cancer has progressed on Tarceva therapy.  Patients without the EGFR mutation represent the vast majority of lung cancer patients. However, such patients generally are not candidates for Tarceva therapy.


In the Phase 2 trial combining REQORSA with Tarceva, subjects received REQORSA in combination with Tarceva every 21 days until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or study treatment discontinuation for other reasons, whichever occurred first. We believe that the results from the Phase 2 trial are encouraging. Out of 10 patients, 9 had received 2 or more cycles and were therefore evaluable for response. Four patients had tumor regression. The median duration of response is three months. The disease control rate (CR+PR+SD > 8weeks) was 78%, which substantially exceeds the 7% response rate (with no CRs) and 58% disease control rate reported for the LUX-Lung 1 trial, a clinical trial of Gilotrif (afatinib) in a comparable group of patients.

REQORSA + Tarceva Combination: Phase 2 data in subjects with or without EGFR mutationsACCLAIM-1 COMBINING REQORSA™ IMMUNOGENE THERAPY WITH TAGRISSO (OSIMERTINIB)Preliminary analysis of the interim data from the Phase 2 portion of our ONC-002 trial supported our belief that REQORSA™ may provide medical benefit in several subpopulations of NSCLC patients for which there is an unmet medical need, and may provide pathways for accelerated approval by the U.S. Food and Drug Administration, or FDA. Data from our clinical trials, along with our preclinical data, provided the basis for our application for a Fast Track Designation, which was granted by FDA on January 14, 2020.In granting our Fast Track Designation, the FDA found that REQORSA may provide a benefit over existing therapies for patients whose tumors progress on AstraZeneca’s Tagrisso. The FDA Fast Track Designation is for use of REQORSA in combination with TKI Tagrisso for the treatment of NSCLC patients with EGFR mutations whose tumors progressed after treatment with Tagrisso. We believe that the Fast Track Designation provides a clearly defined pathway toward FDA approval of the combination of REQORSA with Tagrisso.We initiated the Acclaim-1 clinical trial in June 2021, a Phase 1/2 clinical trial of REQORSA combined with Tagrisso. To learn more about Acclaim-1, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.ACCLAIM-2COMBINING REQORSA™ IMMUNOGENE THERAPY WITH KEYTRUDA (PEMBROLIZUMAB)Researchers at MD Anderson Cancer Center have conducted preclinical studies evaluating REQORSA™ in combination with anti-PD1 checkpoint inhibitors, including Merck’s Keytruda.Positive and encouraging data indicate that REQORSA is synergistic with immunotherapies.In April 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2 with pembrolizumab, demonstrating that TUSC2 combined with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with human immune cells, that had metastatic lung cancer.In November 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2, pembrolizumab and chemotherapy for the treatment of some of the most resistant metastatic lung cancers. This study found that the combination of TUSC2 increases the effectiveness of pembrolizumab and chemotherapy, and thus, may improve on first-line standard of care for lung cancer.In May 2020, we entered into a worldwide, exclusive license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson for the use of TUSC2 in combination with immunotherapies, including Keytruda, and also for the use of TUSC2 in a three-drug combination of TUSC2, immunotherapy and chemotherapy.In December 2021, we received Fast Track Designation from the FDA for use of REQORSA in combination with the checkpoint inhibitor Keytruda for the treatment of advanced NSCLC patients whose tumors progressed after treatment with Keytruda.In March 2022, we opened the Acclaim-2 clinical trial for patient enrollment, a Phase 1/2 clinical trial of REQORSA combined with Keytruda. To learn more about Acclaim-2, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.

DIA-001
STUDYING GPX-002 IN DIABETIC MICE
Researchers at the University of Pittsburgh have conducted preclinical studies evaluating GPX-002 in diabetic mice models. In vivo mice studies have found that GPX-002 restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.These researchers are continuing to conduct preclinical studies in diabetic primates. Once sufficient preclinical data has been generated, we expect to begin a Phase 1 clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Pdx1/MafA Bibliography page.

ONCOLOGY COMBINATION TREATMENT APPROACH
Our oncology program uses a modern combinational treatment approach to fight cancer, utilizing our lead drug candidate, REQORSA™ immunogene therapy and our unique, proprietary, non-viral ONCOPREX® nanoparticle delivery system combined with approved targeted therapies and immunotherapies. This enables us to offer hope to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them.

ONCOLOGY COMBINATION TREATMENT APPROACH
Our research indicates that when REQORSA, our lead drug candidate for non-small cell lung cancer (NSCLC), is combined with targeted therapies such as Tarceva (erlotinib) or Tagrisso (osimertinib) or with immunotherapies such as Opdivo (nivolumab) or Keytruda (pembrolizumab), REQORSA is synergistic with those drugs, meaning that the combination is more effective than either drug alone. We believe that by combining REQORSA with targeted therapies and immunotherapies, we can extend the benefit of these approved lung cancer drugs into the large majority of patients who do not now benefit from them, either because the patients’ tumors do not have the molecular profiles that indicate effectiveness of those drugs, or because the patients have developed resistance to those drugs after receiving them for some period of time.To learn more about our combination trials utilizing our oncology combination treatment approach, refer to our Pipeline and Clinical Trials pages.

TARGETED THERAPIES
Targeted therapies work by targeting the cancer or disease’s specific gene, protein or tissue that contributes to the disease while sparing normal tissue. Unfortunately, targeted therapies require patients to have an activating genetic mutation specific to the drug. In NSCLC, the vast majority of lung cancer patients do not have the genetic mutations that qualify them for targeted therapies, such as the EGFR or ALK gene. In addition, the few patients who do have the genetic mutation qualifying them to receive targeted therapies are likely to develop resistance to these drugs over time.In January 2020, we received a United States FDA Fast Track Designation for use of REQORSA in combination with EGFR inhibitor Tagrisso for the treatment of NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. The median length of time that patients are treated with Tagrisso before their tumors progress is approximately eighteen (18) months.

IMMUNOTHERAPIES
Immunotherapy is a type of treatment that helps the immune system fight disease. Biomarker testing can help determine if high levels of PD-1/PD-L1 proteins are detected in the patient, signifying that the body’s immune system is not working to fight cancer or disease as it should. These patients could qualify for approved immunotherapies, however, not all patients benefit from immunotherapies.Genprex is conducting preclinical studies to evaluate REQORSA in combination with checkpoint inhibitors. Preclinical data indicate that Genprex’s lead drug candidate is synergistic with checkpoint inhibitors, such as Merck’s Keytruda, meaning that the combination of drugs may be more effective than checkpoint inhibitors alone. Preclinical data also indicates that a three-drug combination of a checkpoint inhibitor, chemotherapy, and REQORSA may be more effective than the two-drug combination of a checkpoint inhibitor and chemotherapy.

MARKET OPPORTUNITY
AstraZeneca’s Tagrisso had more than $4 billion in worldwide gross sales in 2020, and Tagrisso is AstraZeneca’s highest grossing product. Given Genprex’s Fast Track Designation and Tagrisso’s status as the current standard of care in EGFR-mutated NSCLC, we have prioritized the clinical development of REQORSA in combination with Tagrisso. We believe this regulatory pathway positions us well in the $17.9 billion global lung cancer market, especially given the advantages of our Fast Track Designation status.Merck’s Keytruda generated more than $14 billion in worldwide sales in 2020, and Keytruda is Merck’s highest grossing product. Keytruda is the standard of care in non-EGFR mutated NSCLC. Genprex plans to initiate a Phase I/II clinical trial evaluating REQORSA in combination with pembrolizumab.

PROGRAMS
LUNG CANCERCANCER
Cancer
is a complex disease that can start in any site in the body when a tissue grows out of control and inhibits the body’s normal functioning. At the cell level, cancer often involves the dysregulation of multiple genes and cellular pathways, leading to the cell’s inability to maintain proper cellular functions. Re-establishing or blocking these pathways can be done through many therapeutic approaches, including gene therapy. More general information about cancer can be found at The American Cancer Society.

LUNG CANCER
Genprex’s oncology program is focused on developing new treatments for cancer. Our initial therapeutic target is lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

According to the World Health Organization in 2020, lung cancer was the leading cause of cancer deaths worldwide, causing more deaths than colorectal, breast, liver, or stomach cancers. In 2020, there were more than 2 million new lung cancer cases and 1.8 million deaths from lung cancer worldwide. In the United States, according to the American Cancer Society, it is estimated that in 2022 there will be more than 236,000 new cases of lung cancer and more than 130,000 deaths from this disease. NSCLC represents 84% of all lung cancers and the five-year survival rate for patients with NSCLC with distant spread is 7 percent. SCLC represents about 13% of lung cancer patients and the five-year survival rate for patients with SCLC with distant spread is 3 percent. With limited benefit from current therapies, we believe there is a significant unmet medical need for new treatments for NSCLC and SCLC in the United States and globally, and we believe REQORSA may be suitable for the majority of lung cancer patients.

DIABETES
DIABETES
Our diabetes gene therapy candidate, GPX-002, is being developed for the treatment of diabetes.According to the U.S. Center for Disease Control, 37 million Americans, or approximately 11% of the population, have diabetes. It is also believed that more than 96 million Americans have prediabetes, which represents approximately 38% of the U.S. population. The prevalence of this chronic disease is continuing to rise.Chronic diabetes conditions include Type 1 diabetes and Type 2 diabetes, both of which lead to excess sugar in the blood and can cause serious health problems. Left untreated, high blood sugar levels can damage eyes, kidneys, nerves, and the heart, and can also lead to coma and death.

TECHNOLOGY

REQORSA® IMMUNOGENE THERAPY

THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS

Our lead product candidate, REQORSA®  immunogene therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary ONCOPREX® Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. In 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® (osimertinib) in late-stage NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA in combination with Merck & Co’s Keytruda® (pembrolizumab) in late-stage NSCLC patients whose disease progressed after treatment with Keytruda.

The active ingredient in our lead product candidate, REQORSA, is the TUSC2 gene, a tumor suppressor gene.

REQORSA consists of the TUSC2 gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge. REQORSA is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective functions arising in the cancer cell. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance.

We believe that REQORSA, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy used for cancer in humans.

OVERCOMING DRUG RESISTANCE

REQORSA is a pan-kinase inhibitor shown to simultaneously inhibit the EGFR and AKT oncogenic kinase pathways in vitro and in vivo. Once the cancer cell takes up the nanoparticle containing TUSC2, it is reprogrammed to die. Resistance to targeted drugs and checkpoint inhibitors develop through activation of alternate bypass pathways. For example, when PD-1 is blocked, the TIM-3 checkpoint is up-regulated. We believe that REQORSA’s multimodal activity will block emerging bypass pathways, reducing the probability that drug resistance develops.

To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our Clinical Trials and TUSC2 Bibliographypages.

GPX-002

DIABETES GENE THERAPY

GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh. Diabetic mice studies have shown that GPX-002 restored normal blood glucose levels for an extended period of time, which could translate to decades in humans. This gene therapy could not only become a new treatment option for millions of diabetes patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.

The diabetes gene therapy, GPX-002, is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

Image source: Osipovich, Anna & Magnuson, Mark. (2018). Alpha to Beta Cell Reprogramming: Stepping toward a New Treatment for Diabetes. Cell Stem Cell. 22. 12-13. 10.1016/j.stem.2017.12.012.

Diabetic mice studies show that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.

The diabetes gene therapy was developed by Dr. George Gittes, a researcher at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, where preclinical research is ongoing. GPX-002 has been tested in vivo in mice and nonhuman primates. Once sufficient preclinical data has been generated, we expect to begin a Phase I clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.

To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Clinical Trials and Pdx1/MafA Bibliography pages.

ONCOPREX® NANOPARTICLE DELIVERY SYSTEM

THE FIRST SYSTEMIC GENE THERAPY DELIVERY PLATFORM USED IN HUMANS FOR CANCER

Our oncology drug development program utilizes our unique, proprietary non-viral ONCOPREX Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. This platform, originally developed through collaborative research between the University of Texas MD Anderson Cancer Center and the National Institutes of Health, has been optimized to work with our initial product candidate, REQORSA® immunogene therapy.

DESIGNED TO DELIVER CANCER-FIGHTING GENES SYSTEMICALLY

The ONCOPREX platform has been designed and optimized to deliver cancer-fighting genes into the patient’s body systemically. Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells. Our nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and have been clinically shown to deliver molecular kinase inhibitors effectively.

OPTIMIZED PARTICLE SIZE

Our systemic, nanoparticle, non-viral delivery system, which is being used in our clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to be small enough to cross tight barriers in the lungs but large enough to avoid accumulation in the liver, spleen and kidney. The nanoparticles have been shown to be taken up by tumor cells after REQORSA administration at up to 33 times the rate they are taken up by normal cells. The cationic charge of the lipid nanoparticles targets cancer cells, which facilitates endocytosis. Once inside the cancer cell, the TUSC2 gene activates signaling pathways that result in cell destruction or apoptosis.

ENHANCED SAFETY AND EFFICACY DESIGN

We have administered REQORSA to more than 50 patients in Phase 1 and 2 clinical trials using our systemic, proprietary, non-viral delivery system.

A Phase 1 clinical trial showed that systemic, intravenous therapy using the ONCOPREX Nanoparticle Delivery System was shown to selectively and preferentially target primary and metastatic tumor cells, resulting in clinically significant anticancer activity. The nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation.

Our earlier clinical trials have also shown that the ONCOPREX Nanoparticle Delivery System is well tolerated in humans and can safely deliver high therapeutic doses. We believe the ONC-001 clinical trial was the first systemic gene therapy clinical trial using a nanoparticle delivery system to deliver a tumor suppressor gene.

GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM IN NON-SMALL CELL LUNG CANCER AT THE 2023 AACR ANNUAL MEETING

APRIL 19, 2023

NPRL2 Gene Therapy Induces Effective Anti-Tumor Activity in Non-Small Cell Lung Cancer Pembrolizumab Resistant Tumors in a Humanized Mouse Model

Provides Preclinical Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene

AUSTIN, Texas — (April 19, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for the NPRL2 gene (also known as the TUSC4 gene). The studies used the Company’s non-viral ONCOPREX® Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) humanized mouse models and were presented at the 2023 American Association of Cancer Research (AACR) annual meeting, which took place from April 14-18, 2023 in Orlando, Florida.

“We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery system, which is being used in our current REQORSA® clinical oncology programs, presented before some of the world’s leading cancer researchers,” said Rodney Varner, President and Chief Executive Officer at Genprex. “The use of the ONCOPREX® Nanoparticle Delivery System to deliver the NPRL2 tumor suppressor gene positions Genprex to expand our clinical pipeline with a new drug candidate.”

“The preclinical data also provide further evidence that the ONCOPREX® Nanoparticle Delivery System has the ability to be successful using genes other than the TUSC2 gene that we are already using in clinical trials with REQORSA®,” stated Varner. “These compelling outcomes give us further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.”

Genprex’s ONCOPREX® Nanoparticle Delivery System, is a novel non-viral approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for the intravenous delivery of various tumor suppressor genes, and potentially other genes, to achieve a therapeutic affect without the risk of toxicity often associated with viral delivery systems.

Featured Genprex-supported posters presented at AACR 2023 include:

Event: Americal Association of Cancer Research (AACR) Annual Meeting

Session Category: Immunology

Session Title: Combination Immunotherapies 2

Location: Section 22

Session Date and Time: Tuesday, April 18 from 1:30-5:00 p.m. ET

Title: “NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanizedmouse model”

Presenters: Jack A. Roth, MD, The University of Texas MD Anderson Cancer Center

Poster Board Number: 23

Abstract Presentation Number: 5120

The abstract entitled, “NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) in a humanized mouse model,” is available on the AACR website. The presentation reported results from this study, which investigated the antitumor immune responses to NPRL2 gene therapy on anti-PD1 resistant KRAS/STK11 mutant NSCLC in a humanized mouse model. In the study, humanized mice were treated with NPRL2 gene therapy, immunotherapy pembrolizumab (Keytruda®), or the combination. A dramatic antitumor effect was mediated by NPRL2 treatment, whereas pembrolizumab was ineffective. A significant antitumor effect was also found in non-humanized NSG mice, although the antitumor effect was greater in humanized mice, suggesting that the immune response played a role in inducing antitumor activity.

The study data suggest that NPRL2 gene therapy induces antitumor activity on KRAS/STK11 mutant anti-PD1 resistant tumors through DC mediated antigen presentation and cytotoxic immune cell activation.

A KRAS mutation occurs in approximately 25% of patients with NSCLC, and one study found that KRAS/STK11 combination mutations were found in approximately 6.5% of NSCLC patients.

“These data are encouraging because they not only validate Genprex’s non-viral oncology platform to deliver a variety of tumor suppressor genes, but they also provide further evidence of the important role that tumor suppressor genes play in cancer, particularly NSCLC,” said Mark Berger, MD, Chief Medical Officer at Genprex. “KRAS is the most frequent oncogene mutated in NSCLC, and KRAS mutations are often associated with resistance to drug therapy[i]. Targeting KRAS/STK11 mutant NSCLC with the NPRL2 gene, and potentially with anti-PD1 as well, may provide therapeutic potential for this group of lung cancer patients.”

Genprex currently has three clinical trials evaluating the Company’s lead drug candidate, REQORSA® Immunogene Therapy (quaratusugene ozeplasmid) in lung cancer. The Acclaim-1 clinical trial, which received FDA Fast Track Designation, is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA in combination with Tagrisso® (osimertinib) in patients with late-stage NSCLC with activating epidermal growth factor receptor (“EGFR”) mutations whose disease progressed after treatment with Tagrisso. The Acclaim-2 clinical trial, which received FDA Fast Track Designation, is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA in combination with Keytruda® (pembrolizumab) in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda. The Acclaim-3 clinical trial, expected to open for enrollment by the end of the third quarter of 2023, is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA in combination with Tecentriq® (atezolizumab) in patients with extensive-stage small-cell lung cancer (SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as an initial treatment.

INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

APRIL 18, 2023

Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo

Study adds to the growing body of research examining TUSC2 as a target for multiple other cancers

TUSC2 is the tumor suppressor gene used in the Company’s lead drug candidate, REQORSA® (quaratusugene ozeplasmid)

AUSTIN, Texas — (April 18, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that independent researchers recently presented preclinical data on the tumor suppressor gene, TUSC2, reporting that it functions as a novel tumor suppressor for glioblastoma. TUSC2 is the tumor suppressor gene that is reexpressed in tumors using REQORSA® Therapy treatment, Genprex’s lead drug candidate. Genprex has no affiliation with these researchers.

The independent researchers presented their abstract, titled, “Investigating TUSC2 for its tumor suppressive functions in glioblastoma and its role in gliomagenesis,” at the 2023 American Association for Cancer Research Annual Meeting on April 17. The abstract reports TUSC2 protein expression, but not mRNA expression, to be significantly decreased in glioblastoma as compared to normal brain. TUSC2 protein is destabilized in glioblastoma due to polyubiquitination by E3 ligase, neural precursor cell-expressed developmentally downregulated gene 4 (NEDD4), and degradation by the proteasome. The researchers determined that NEDD4 targets TUSC2 on lysine residue K71.

The researchers also reported that TUSC2 overexpression reduced colony formation and neurosphere formation and promoted apoptosis of glioblastoma cells in vitro, and suppressed tumor growth in vivo. Further, glioblastoma cells with CRISPR-mediated knockout (KO) of TUSC2 were highly aggressive in vitro and in vivo, demonstrating the role of TUSC2 as a novel tumor suppressor for glioblastoma.

In the study, researchers performed immunoprecipitation-mass spectrometry analysis to identify TUSC2-interacting proteins in both normal human astrocytes and glioblastoma cell lines. Results showed 95 and 88 TUSC2-interacting proteins in astrocytes and glioblastoma cell lines respectively, and 27 proteins were found to interact with TUSC2 in both astrocytes and glioblastoma.

“This research supports the growing body of studies evaluating TUSC2 as a target in oncology, and potentially an effective treatment, for many types of cancer,” said Rodney Varner, Chairman, President and Chief Executive Officer of Genprex. “We are encouraged by the increasing number of research institutions and independent researchers producing positive data on TUSC2, which provide additional support for REQORSA® and its therapeutic potential against cancers.”

REQORSA® Therapy is currently in development for the treatment of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). REQORSA® consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (the Company’s ONCOPREX® Nanoparticle Delivery System) with a positive electrical charge. REQORSA® is injected intravenously and specifically targets cancer cells, taking advantage of leaky tumor vascularity, increased tumor pinocytosis, and attraction of positively charged lipid nanoparticles to negatively charged cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue.

According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers. More than 13,000 Americans were expected to receive a glioblastoma diagnosis in 2022. Glioblastoma accounts for 49.1 percent of all primary malignant brain tumors. There have only been five drugs and one device ever approved by the U.S. Food and Drug Adminstration for the treatment of glioblastoma.

Other independent researchers and studies have found that TUSC2 therapy may benefit other types of cancer, including head and neck, breast (including triple-negative breast cancer), renal cell (kidney), thyroid, and soft tissue sarcoma, as well as NSCLC and SCLC. For more information and additional studies supporting TUSC2, please refer to our Bibliography Page.

NEWS

GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM IN NON-SMALL CELL LUNG CANCER AT THE 2023 AACR ANNUAL MEETING

APRIL 19, 2023

Provides Preclinical Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene

Read More


INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

APRIL 18, 2023

Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo

Read More


GENPREX CEO COMMENDS FDA’S INITIATIVE TO ACCELERATE APPROVAL PROCESS FOR GENE THERAPIES

MARCH 23, 2023

Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options

Read More


GENPREX TO PRESENT AT BIOPROCESSING SUMMIT CONFERENCE

MARCH 13, 2023

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies

Read More


GENPREX TO PARTICIPATE IN MARCH INVESTOR AND INDUSTRY CONFERENCES 

MARCH 8, 2023

Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes

Read More


GENPREX, INC. ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING WITH A SINGLE, HEALTHCARE-FOCUSED INSTITUTIONAL INVESTOR

FEBRUARY 27, 2023

The gross proceeds from the offering are expected to be approximately $4 million, before deducting placement agent fees and other estimated offering expenses.

Read More


GENPREX ANNOUNCES GROUNDBREAKING DATA FROM NON-HUMAN PRIMATE STUDY EVALUATING NOVEL GENE THERAPY TO TREAT TYPE 1 DIABETES AT 16TH ANNUAL INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENT FOR DIABETES 2023

FEBRUARY 23, 2023

Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline

Read More


GENPREX SIGNS EXCLUSIVE LICENSE TO ADDITIONAL DIABETES TECHNOLOGY WITH THE UNIVERSITY OF PITTSBURGH

JANUARY 5, 2023

Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes

Read More


GENPREX ANNOUNCES SELECTION OF PRECLINICAL DATA FOR ORAL PRESENTATION AT 16TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES 

JANUARY 4, 2023

Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex’s Gene Therapy Program in Diabetes to be Showcased

Read More

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

DECEMBER 15, 2022

Technology for modulating autoimmunity expands intellectual property portfolio

Read More


GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO PROCEED TO FINAL COHORT IN ACCLAIM-1 PHASE 1 DOSE ESCALATION TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER

DECEMBER 14, 2022

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer

Read More


MANAGEMENT

Check out the management team here: https://www.genprex.com/about/company-management/

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVENTEEN THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LEGENDS MEDIA  FOR A ONE DAY GNPX AWARENESS CAMPAIGN. WE HAVE PREVIOUSLY BEEN COMPENSATED FIFTY SEVEN THOUSAND FIVE HUNDRED USD IN TOTAL TO COVER GNPX. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: BTCY) Profile

OUR NEW PROFILE IS: (NASDAQ: BTCY)

___________________________________

Revenue is up 27.4% YOY

 

Residual revenues are driven by a 95% retention rate

 

Biotricity surpasses $10 million in annual revenue run rate

 

Bioheart named to TIME’s list of The Best Inventions of 2022′

 

Biotricity surpasses 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib)

 

CHECK OUT THE INVESTOR PRESENTATION HERE

 

_______________________________

Hello Everyone, We have another exciting profile we want you to research for Mondy’s session. This a company that we have never featured on our newsletter before. It has closed green 5 of the last 7 and was up 13% today at the close on light interest. Timing is everything and we think that we could be a good time to research this one. It is under .55 right now with a 52 week high several hundred percent about it’s current levels. Turn your attention to Nasdaq: BTCY. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. There is an ongoing shift in healthcare towards preventive care, which Biotricity is leveraging to modernize chronic care & disease management.
The company believes its diagnostic and post-diagnostic solutions help reduce healthcare costs and detect anomalies earlier than existing monitoring solutions and provide faster and better reporting, as well. BTCY has expanded its salesforce in 2022 and targets further penetration into doctor’s offices and clinics with the recent launch of Biotres and the upcoming launch of other products. The company believes its tech platform is disrupting the traditional cardiac care model. With Biotricity’stechnology, cardiac patients can access advanced diagnostics from their homes using Biotricity devices, and thereby minimize visits to the cardiologist or hospital to times when therapeutic treatment or procedures are needed. The company’s lead product, Bioflux, is designed to detect an arrhythmia, heart attack, ventricular or atrial issue faster and transmit the information to a call center to prevent a traumatic health event faster than a conventional Holter device. As BTCY moves to grow its share in the cardiac health cloud service niche, the company also seeks to expand horizontally beyond the cardiac market. Biotricity believes its emerging ecosystem offers a user- friendly platform that can be applied to help people suffering with diabetes, obesity, hypertension, sleep apnea, pain management and potentially many other areas. The company launched Biotres earlier this year. It is a wearable wireless 3-lead patch device for continuous recording of ECG heart data and wider array of arrythmia monitoring.
As BTCY initiatives measures to grow its share in the cardiac health cloud service niche, the company also seeks to expand horizontally beyond cardiac and believes its emerging ecosystem offers a user-friendly platform that can be applied to monitor and assist people suffering with diabetes, obesity, hypertension, sleep apnea, pain management and potentially many other areas of healthcare management.
BTCY CATALYSTS
  • Unveiled our personal medical device kit, Biokit, for integration into our Biotricity ecosystem
  • Unveiled, Bioheart, a first-of-its kind continuous heart rhythm recorder and personal heart and lifestyle solution
    • The Company’s Bioheart personal cardiac monitor won TIME’s Best Inventions of 2022.
    • Awarded $250K NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure.
    • Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib).
    • Launched Biocare Cardiac Disease Management Solution after two successful pilots at Oklahoma & Kentucky Clinics.
    • Continued expansion of our network and maintenance of a 95+% retention rate that together drive Biotricity’s residual revenues.
      • Operating Highlights for the Q3-FY23 to Date
        • Signed agreements with two leading US medical device distributors and one GPO
        • Launched Biocare Cardiac Disease Management Solution which is gaining traction, early adoption, and is provided as a bundled service offering to clinics and hospitals
        Q3-FY23 Financial Highlights
        • Revenue totaled $2.46 million
        • Gross profit totaled $1.4 million
        • Gross margin of 57%
        • Net loss totaled $4.75 million, or $0.091 per share
 

Biotricity signs distribution agreement with top 5 distributor for its Cardiac Monitoring Solutions

REDWOOD CITY, Calif., Jan 26, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced it has signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of its two cardiac monitoring solutions (CMS) designed for cardiologists’ patient use – Bioflux® and BiotresTM. The distribution agreement covers Bioflux and Biotres and will be distributed directly to hospitals and clinics for professional medical utilization with suitable patients. Commenting on the agreement, Biotricity Founder, Chairman and CEO Waqaas Al-Siddiq, Ph.D., said, “The future of healthcare lies with new, state-of-the-art technology that produces a more efficient and higher quality of care through remote care. That means tech that is specially designed for smart remote monitoring of individuals using digital/wireless and cloud-based technology with seamless integration with all platforms and devices. “Our Bioflux and Biotres solutions address a market valued at $6 billion, and we fully expect to capture an increasing share of this growing marketplace,” Dr. Al-Siddiq added. “We are delivering cardiac care remotely, 24/7 and in real-time as needed, with technology that rivals existing standard of care solutions. Long term, we are confident our technology, and the lifestyle improvements it encourages will bend the curve of growing rates of heart disease.” biotricity

_________________

Biotricity’s Enviably Massive Addressable Markets According to the World Health Organization, Cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. We are determined to reduce that number in a meaningful way, as our growing success addresses a heart rate monitoring devices market of $12.4 billion globally that analysts project reaching $17.1 billion in 2026. As a company, our focus is on expanding our total addressable market (TAM) by executing on our product portfolio. This will increase our TAM from $1.7 for cardiac devices to $55.9 Billion for Telemedicine andvcare management. Suffice to say, we have an enourmous opportunity ahead, I believe these forecasts are low and do not yet factor in our technology’s superior capabilities and industry & patient health, wellness, and lower-cost benefits.
  • Cost Savings & Workflow Time Efficiency for Nurses. Instead of expensive hospitals and emergency room bills, pro-active monitoring and early detection of medicine need or surgery allows outpatient cost savings. Remote monitoring allows cost-effective at $11,000/year (NIH/Journal of Cardiovascular Electrophysiology) per patient year.
  • Reimbursement rates reduction or cut risk from Medicare is minimal exposure for Biotricity and its physicians network. Bioflux and the recently launched Biotres patch already fit into the existing billing codes and resilient clinical fee. Biotricity’s wheelhouse is more insulated because no reimbursement specialist is needed for billing and reads are insurance reimbursable.
  • Recurring revenue play and easily deployable tech. There is also lower operational expense for the doctors and clinics, along with easy integration into their back offices. Rechargeable devices help keep the margins high and further insulate from reimbursement.
  • Detection & Accuracy are improved with Bioflux compared to conventional products. Artificial Intelligence (AI) and Biotricity’s database on nearly 100,000 patients of ECG data can identify ECG abnormalities with 90%+ accuracy and speed up response time, according to BTCY.
  • Beneficiary of the ongoing shift to remote monitoring of outpatients and improved efficiency for doctors and nurses workflow. Physicians benefit from earlier detection of patient’s heart issues, improved workflow and efficiencies with Biotricity’s software and automation. The physician can increase their own annual revenues by approximately $180,000-260,000 as seen below.

Biotricity reports financial results for Fiscal 2023 Third Quarter

  • Revenue Up 27.4% YOY
  • Enviable 98% Customer Retention Rate Drives Subscription Recurring Rev Growth
  • Two Major Distribution Agreements Implemented
  • Net Loss Narrowed by One Third as Company Targets Positive Cash Flow
  • Investor Teleconference Scheduled Today for 4:30 ET
February 14, 2023 | BY BIOTRICITY
REDWOOD CITY, Calif., Feb 14, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced its financial results and provided a business update for its third quarter of fiscal 2023 ended December 31, 2022. Commenting, Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “With our suite of state-of-the-art remote cardiac solutions now well established, Biotricity is focused on sales, marketing and achieving positive cash flow. In just the past three months, we have successfully signed agreements with two leading US medical device distributors and one Group Purchasing Organization (GPO) as major components of our go-to market strategy and growing marketplace prominence. In total, just in the US alone, they cover over $20 billion in annual purchasing. We are actively considering adding similar distributors with geographic or vertical coverage that complement our existing networks. “Technologically, we are increasingly leaning into AI with its data and predictive capability to target more pervasive forms of patient monitoring and lifestyle management. Our enviable 98 percent customer retention rate succinctly reflects our strong competitive position. It also ensures our customers’ lifetime value is high and drives our growing ‘technology-as-a-service’ base of recurring revenue. “Financially, we reported strong sales revenue growth of 27.4 percent year-over-year, and a gross margin of 57 percent as our business scales, while narrowing the net loss by one third. In calendar year 2023, we plan to trim R&D and capex while continuing to innovate products and services centered around our cloud-based Biosphere cardiac ecosystem — to reduce the overall price of unrivaled cardiac care while positively transforming the efficacy of its delivery and outcomes. “Looking ahead, we are focused on increasing market penetration through additional distribution agreements, highly targeted advertising, industry conference and tradeshow participation, and building our sales and marketing team one carefully selected professional at a time, all while managing cash flow to accelerate our path to profitability.” Operating Highlights for the Q3-FY23 to Date
  • Signed agreements with two leading US medical device distributors and one GPO
  • Launched Biocare Cardiac Disease Management Solution which is gaining traction, early adoption, and is provided as a bundled service offering to clinics and hospitals
Q3-FY23 Financial Highlights
  • Revenue totaled $2.46 million
  • Gross profit totaled $1.4 million
  • Gross margin of 57%
  • Net loss totaled $4.75 million, or $0.091 per share
Full details of the Company’s financial results will be filed with the SEC on Form 10-Q, and are available at no cost by visiting www.sec.gov. Financial Results Conference Call Management will host a conference call on Tuesday, February 14, 2023 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter and provide a business update. Additional details are available under the Investor Relations section of the Company’s website: https://www.biotricity.com/investors/
Biotricity Product Roadmap Bioflux® is their flagship product. It is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients’ ECG information.
Disruptive Business Model
  • Insourced business model, enabling physicians to bill directly
  • Minimal upfront cost for physician, physician pays only when device is used – top line profit
  • Turn-key solution for physicians
  • Recurring revenue with high margin for Biotricity
  • Reads are insurance reimbursable using existing CPT billing codes
  • Turn-key solution: device, software, and monitoring center • One piece device that is the smallest in the market
  • Built-in global GPS and GSM platform

CURRENT FOOTPRINT FOR BIOFLUX

Biotres is a three-lead patch solution for real-time and passive arrhythmia monitoring designed for patients who are at risk for, or diagnosed with, certain cardiac issues. It can operate as a Holter, Event Loop, and potentially as a wireless patch in conjunction with Bioflux for MCT. Biotres has been filed with the FDA and is pending approval.
page12image507305248
Biocare® Telemed is a virtual clinic platform with secure HIPAA-compliant technology that enables clinicians to provide outstanding patient care remotely, ensuring their at-risk patients and those needing remote cardiac monitoring do not have to leave the safety and comfort of their home. Today, the Biocare app is used by our customer clinics to service their patients. Going forward, it will become a virtual cardiac clinic where individuals looking for a cardiologist will be able to access our network of cardiologists. To achieve this, we are currently interconnecting our customer clinics to create one large virtual cardiac clinic, which we expect to launch in the second half of 2022. This will enable individuals looking for a cardiologist to access one that uses the Biotricity eco-system of diagnostics and disease management technology. Biokit is a personal medical device kit, a bundled home-use set comprised of a digital thermometer, a pulse oximeter, and a blood pressure cuff. It is FDA cleared, wireless capable and readily integrates into the Biotricity eco-system. Introduced in September, it is slated for a 1Q-22 launch. With Bioflux and Biokit combined, we will soon offer a comprehensive cardiac diagnostics and management product line for effective, accurate and economic long-term disease management.
Bioheart is for consumers seeking self-management of pre-diagnosis heart health, wellness and preventative care. Consumers can share data with their physicians if they choose. Following strong sales during its pre-release period, we launched Bioheart earlier this month – ahead of schedule – and plan to ramp up its marketing campaign throughout 2022.

Biotricity surpasses $10 million in annual revenue run rate

REDWOOD CITY, Calif., Nov 21, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced it has surpassed $10 million in annual revenue run rate. “With strong revenue growth each quarter, our scale and market reach increases every day,” says Biotricity Founder and CEO, Dr. Waqaas Al-Siddiq. “I am committed to continuing to drive growth and realize our potential. Our focus remains on providing the cardiac health market with disruptive, superior digital and AI technology at competitive pricing with unrivaled support to our customers and physician partnerships.” Biotricity boasts multiple ground-breaking products including Bioflux®, Biotres, and Bioheart which won TIME’s Best Inventions of 2022.
  • Bioflux: a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of your ECG information to your doctor
  • Biotres: an easy to wear, rechargeable device with wireless capability, utilizing the advanced technology of the Bioflux® for more active days
  • Bioheart: a consumer-targeted continuous heart rhythm monitor that uses the most advanced heart technology to deliver unlimited heart data insights with three views of your heart
The record revenue run rate is Biotricity’s latest achievement in a string of major milestones that include:
  • The Company’s Bioheart personal cardiac monitor won TIME’s Best Inventions of 2022
  • Awarded $250K NIH grant from the National Heart, Blood, and Lung Institute for AI-enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure
  • Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation (A-fib)
  • Company has delivered revenue growth in nine out of the last ten consecutive quarters

Biotricity’s Bioheart named to TIME’s list of The Best Inventions of 2022

Bioheart provides consumers the most advanced personal heart monitoring technology, combining powerful analytics and continuous heart monitoring for personalized heart insights

November 10, 2022 | REDWOOD CITY, Calif., Nov 10, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that its Bioheart device has been named to TIME’s list of the Best Inventions of 2022. Bioheart is the first of its kind – a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights.
Cardiac issues are intermittent, often asymptomatic, and lifelong in nature, requiring continuous heart activity monitoring. Fitness trackers simply collect your heart rate and personal ECG devices manually collect a few minutes of data, leaving you without the full picture. Bioheart changes everything by creating the first heart activity monitor. Whether you are sleeping, sitting, or out exploring the world, Bioheart’s uninterrupted monitoring keeps you informed about your heart 24/7. TIME reveals its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives: time.com/best-inventions-2022. To compile the list, TIME solicited nominations from TIME’s editors and correspondents around the world, as well as through an online application process, paying special attention to growing fields-such as the electric vehicle industry, green energy, and the metaverse. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. Of the New Best Inventions list, TIME’s editors wrote: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)- including life-mapping artificial intelligence, diamonds made from excess carbon in the air, and the most powerful telescope ever-that are changing how we live, work, play, and think about what’s possible.” “We are honored and excited to have our premier consumer product, Bioheart, included in TIME’s 2022 list,” commented Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Our mission is to disrupt and transform the state of cardiac health and wellness, worldwide. Bioheart is the beginning of this journey”

ANALYST RATINGS

There are several analysts with price targets on BTCY well above it’s current levels of a dollar. They all represent 300%+ moves from it’s current levels if the analysts turn out to be right. (sourced from MarketBeat)

Biotricity surpasses 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib)

Data set of 2 billion heartbeats and growing allows Biotricity to scale faster and operate more efficiently with better automation, yielding growth and better margins in the future

REDWOOD CITY, Calif., Oct 04, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient’s ECG information, has captured billions of heartbeats to date, monitored in real-time by Bioflux’s built in algorithms, certified cardiac technicians and benchmarked by Artificial Intelligence (AI). Leveraging the Company’s proprietary AI, over 2 billion of the total heartbeats to date have been segmented for AFib analysis. According to Emergen Research, the global recurrent market for AFib is expected to reach USD$26 billion by 2027, growing at a CAGR of 13.2%. This large data set provides further benefits for patients, providers and ultimately clinical research for the future of predictive monitoring. Additionally, it allows Biotricity to scale faster and operate more efficiently, develop better automation, yielding growth and better margins in the future. The consistent focus on R&D and data capture has positioned Biotricity with a significant competitive advantage in key cardiac segments of the market, such as AFib. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “AFib unfortunately continues to be a leading cardiac risk globally, growing annually at alarming rates. We have purposely designed our ecosystem to monitor the patient 24/7 while leveraging our innovative technology that uniquely combines AI with data and predictive capabilities. In doing so, we can create better and faster analytics for preventative patient monitoring and lifestyle management. For AFib specifically, the ability to significantly narrow the time of diagnosis reduces risk for the patient and liability for the provider, giving our technology the ability to positively impact millions who suffer with AFib globally. Additionally, as we continue to collect more data through our R&D efforts, our internal quality review process will scale and further increase in efficiency, allowing us to continue to grow our margins.”

CHART

NEWS

Biotricity-ImpactReport-W2

Leading medical biometric firm Biotricity releases first corporate impact report

REDWOOD CITY, Calif., Apr 11, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a leading medical diagnostic and consumer healthcare technology…
PR-Milestones-uai-258x129

Medical biometric firm Biotricity reshaping market through pioneering innovation

REDWOOD CITY, Calif., Mar 07, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
2023-Q3-FinancialResults-Call-scaled-uai-258x129

Biotricity reports financial results for Fiscal 2023 Third Quarter

REDWOOD CITY, Calif., Feb 14, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
2023-Q3-FinancialResults-scaled-uai-258x129

Biotricity To host Fiscal 2023 Third Quarter Financial Results call on February 14th at 4:30pm ET

REDWOOD CITY, Calif., Feb 09, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
W1-Feb-03-ISC23-uai-258x129

Biotricity selected to present its work on AI enabled stroke prediction in CKD patients at the 2nd Annual Innovation Showcase during the American Stroke Association 2023 International Stroke Conference

REDWOOD CITY, Calif., Feb 03, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Biotricity-PR-BiofluxBiotres_W3_Jan25

Biotricity signs distribution agreement with top 5 distributor for its Cardiac Monitoring Solutions

REDWOOD CITY, Calif., Jan 26, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Biotricity_Maxim_W3_Jan23-uai-258x129

Biotricity to participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, January 25th at 8:15 A.M. ET

REDWOOD CITY, Calif., Jan 23, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
W3-Jan-16-PR_GPO-uai-258x129

Biotricity signs with top 5 group purchasing organization; potential for higher sales volume in 2023

REDWOOD CITY, Calif., Jan 17, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,
Biotres with FDA 510K

Biotricity files FDA 510(k) for a new form factor of its Biotres Cardiac Monitoring Device to expand its revenue growth

REDWOOD CITY, Calif., Dec 12, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Biotricity-10M-Earnings-W4-Nov-21-uai-258x129

Biotricity surpasses $10 million in annual revenue run rate

REDWOOD CITY, Calif., Nov 21, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Expansion

Biotricity provides updates on its operational and expansion strategy

REDWOOD CITY, Calif., Nov 18, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Boxes ready for distribution

Biotricity signs Distribution Agreement to expand access for its Cardiac Monitoring Solutions

REDWOOD CITY, Calif., Nov 16, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
2023-Q2-Earnings-uai-258x129

Biotricity reports financial results for Fiscal 2023 Second Quarter

REDWOOD CITY, Calif., Nov 14, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Bioheart in the Times list of best inventions 2022

Biotricity’s Bioheart named to TIME’s list of The Best Inventions of 2022

REDWOOD CITY, Calif., Nov 10, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Fiscal Second Quarter

Biotricity to host Fiscal 2023 Second Quarter financial results on November 14th at 4:30 PM ET

REDWOOD CITY, Calif., Nov 01, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Biocare Cardiac

Biotricity launches Cardiac Disease Management Solution following 2 successful pilots with Oklahoma & Kentucky Clinics

REDWOOD CITY, Calif., Oct 26, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
American Medical Device Summit

Biotricity CEO, Waqaas Al-Siddiq, to participate in panel discussion on the evolution of medical devices at the American Medical Device Summit on October 19th

REDWOOD CITY, Calif., Oct 11, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Biotricity_Afib_W1_Oct4_r3
Biotricity-10M-Earnings-W4-Nov-21-uai-258x129

Biotricity surpasses $10 million in annual revenue run rate

REDWOOD CITY, Calif., Nov 21, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…

Biotricity surpasses 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib)

REDWOOD CITY, Calif., Oct 04, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
bioflux-ai

Biotricity wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure

REDWOOD CITY, Calif., Sep 07, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company,…
Fiscal First Quarter 2023

Biotricity reports financial results for Fiscal 2023 First Quarter

REDWOOD CITY, Calif., Aug 15, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), (“Biotricity” or the “Company”), a medical diagnostic and…

Management Team

Dr. Waqaas Al-Siddiq, Phd

Chairman, CEO & Founder
Waqaas, the founder of Biotricity, is a serial entrepreneur, a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council. Waqaas has held several high-level design positions in IBM, AMD, and Intel. His achievements have been numerous in both the technical and academic world. Coupled with this, Waqaas has vast experience in leading various groups through his board experience and executive roles within start-ups, mid-sized companies, and non-profits. Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration from Henley Business School. He also holds a Doctorate in Business with a specialty in Transformative Innovations and Billion Dollar Markets.

Norman Betts, Phd

Independent Board Member
Norman sits on the Boards of Directors of the Bank of Canada, Tembec Inc., New Brunswick Power Corporation, 49 North Resources Inc., Adex Mining Inc., Tanzanian Royalty Exploration Inc. and the University of New Brunswick Pension Plan for Academic Employees. Norman is an Associate Professor in the Faculty of Business Administration at the University of New Brunswick in Fredericton. He is accomplished in the field of accounting and finance, with a mix of academic, public, and private-sector experience. He is an expert in accounting regulations, and has extensive experience in audits, risk management, governance and oversight. He was a member of the New Brunswick Legislative Assembly from 1993 to 2003 and held three different cabinet posts, including Minister of Finance from 1999 to 2001. Prior to entering politics, Norman was Assistant Dean of the MBA Programme and an Associate Professor at the University of New Brunswick as well as a partner in the accounting firm Shannon, Betts & Buffett. Norman received a PhD in Management with a concentration in accounting and finance from Queen’s University School of Business in 1992 and a Bachelor of Business Administration from the University of New Brunswick in 1978. He also holds a Fellow Chartered Accountant designation.

Dave Rosa

Independent Board Member
Dave has spent the past 22 years in a variety of positions in the medical device industry. He was appointed CEO of Sunshine Heart in October of 2009 and served as President and Chief Executive Officer through November 2015. Dave took Sunshine Heart Public on NASDAQ in 2012 and raised over $120M during his tenure. The Company achieved a number of clinical, regulatory and research and development milestones under his leadership. Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Dave was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he developed the strategic pan for the newly formed interventional division, directed the launch of several new products and oversaw the acquisition and integration of Velocimed, a privately held company in the cardiovascular space. From 1999-2004, Dave held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that developed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, Dave served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific. Dave holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.

Patricia Kennedy

Independent Board Member
Patricia has spent over 25 years in a variety of global sales and distribution positions in the medical device industry, focusing on the field of Electrophysiology. In 2015, she founded and is currently the Managing Director of PJM Medical Consultants, supporting medical device companies entering the international market with market entry and product commercialization strategies. From 2008 to 2015, Pat served as VP – International and General Manager for Atricure, Inc. She achieved significant sales, market development and clinical science milestones, while defining strategic plans and pursuing technology development and acquisitions. From 2001 to 2008, Pat worked with Stereotaxis, Inc. in numerous executive positions including Worldwide VP – Clinical Services and VP – International Sales and Marketing. Prior to Stereotaxis, Pat worked with EP MedSystems as International Marketing Manager for defibrillation and diagnostic catheters. She began her career in the medical industry at Boston Scientific from 1992 to 1997 while serving in several positions, including Sales and International Product Manager for EPT. Pat has earned a Bachelor of Science Degree in Marketing from the University of Florida and a Bachelor of Science in Nursing degree from the University of North Florida.

Steve Salmon

Independent Board Member
Steve Salmon has expertise in business development transactions, market development, finance, technology, and capital market. His most recent experience was as a Venture Capitalist for Latterell Venture Partners, where he managed a number of portfolio companies. Prior to becoming a VC, Mr. Salmon was a founder of Ensure Medical and Integrated Vascular Systems, both of which were successfully exited through acquisition. He also served as the CEO of Revascular which was also acquired. Mr. Salmon brings to Biotricity his deep expertise in raising capital, facilitating growth, and driving long term value.

John Ayanoglou

Chief Financial Officer
John has over 25 years of accounting, finance, and operations experience, having previously served as CFO of several public companies and a regulated financial institution. As CFO of Equitable Group, Mr. Ayanoglou raised over $130 million of regulatory capital in common, preferred, and debenture offerings over successive transactions, all during a period of extreme capital market turbulence, helping to successfully grow assets under administration from $6.1 billion to over $10 billion to facilitate Equitable Bank in becoming Canada’s ninth largest bank. He was also the CFO and Corporate Secretary of Xceed Mortgage Corporation, where he partnered with an entrepreneurial top team to grow the business through the successful implementation of warehouse financing lines and other securitization programs including public term securitizations of over $700 million. John has extensive experience as a trusted business advisor working with management teams and boards on business acquisition and consolidation, risk mitigation and turnaround, to establish efficient, effective operations. He is a CA, CPA with a Bachelor of Commerce degree in Finance and Economics from the University of Toronto and his ICD.D designation from the Institute of Corporate Directors and the Rotman School of Business.

Amir Ali

Chief Development Officer
Amir is a serial entrepreneur with over 20 years of experience in launching companies and producing innovative products, services, and solutions. Amir is sought after for his expertise in transforming R&D technologies into products based on market needs, commercializing products for volume production, and establishing global distribution channels across the world. Prior to joining Biotricity, Amir served as CEO at AT Labs Inc., where his team pioneered the concept of wireless mobile thin clients to access secure enterprise applications through the cloud. The efficacy of the robust solutions resulted in customers from healthcare, government, enterprise, and retail sectors, most of which spanned thousands of locations across the United States. His experience in developing such novel technologies has put him at the forefront of companies that have grown in revenue from zero to over $160 million. In his own ventures, he has worked with many leading industrial and financial institutional funders including Jafo, Bay Partners, and JP Morgan with whom he has raised over $35 million.
Spencer LaDow
Vice President, Engineering
Spencer is an expert in wireless communication and has worked with the United States Department of Defense. His academic career was highlighted by various innovative projects and designs. Spencer obtained his undergraduate degree while balancing a full-time job at Flightline Systems Ultra Electronics, a small defense contractor. His specialties are in the design and implementation of radio frequency, digital, analog, embedded software and PC software. Spencer also has experience in working with marketing, sales, and manufacturing teams in order to develop products for large-scale output. Spencer has a Bachelor’s degree in Computer Engineering from Rochester Institute of Technology.

Advisory Board

Thomas C. Nelson

Nelson serves as the president of Share Our Strength, a national nonprofit that is ending childhood hunger in America. Prior to joining Share Our Strength in 2011, Nelson was chief operating officer for AARP, where he led the build-out of its state strategy in all 53 US states and territories. In addition to serving as an adjunct professor at Georgetown University’s McDonough School of Business, Nelson has a long history of service to civic organizations, including his current position on the board of directors of ProInspire. Other board positions include, the board of counselors for the Davis Gerontology School at the University of Southern California; the board of the Certified Financial Planner Board of Standards; and the board of Community Wealth Partners. Nelson holds a Ph.D. from the University of Southern California and an M.A. from Columbia University.

John Rother, JD

Mr. Rother is President and CEO of the National Coalition on Health Care, America’s oldest and most diverse group working to achieve comprehensive health system change. Prior to joining the Coalition in 2011, Rother worked at AARP for over 27 years as the Executive Vice President for Policy, Strategy, and International Affairs where he led the development of AARP’s policy positions and advocacy strategies. Under his leadership, AARP engaged in public policy research and analysis, public education, and advocacy on health and retirement issues at the federal, state and international levels. Rother wrote numerous articles and was a frequent speaker on health, retirement security, the federal budget, and the boomer generation. Prior to that, Rother was Staff Director and Chief Counsel for the U.S. Senate Special Committee on Aging under the direction of Chairman John Heinz and served as Special Counsel for Labor and Health to U.S. Senator Jacob Javits. He has consistently been named as one of the most powerful people in Healthcare and in 2010 received the Robert Ball Award for Outstanding Achievements in Social Insurance from the National Academy of Social Insurance for “lifetime advocacy to strengthen Social Security and Medicare.”

Daniel Sands, MD, MPH

Dr. Sands is passionate about healthcare transformation, non-visit based care, collaboration in healthcare, and participatory medicine. He spent six years at Cisco, as chief medical informatics officer, where he provided both internal and external health IT leadership and helped key customers with business and clinical transformation using IT. Sands’ prior position was chief medical officer for Zix Corporation, a leader in secure e-mail and e-prescribing. Sands also spent 13 years at Beth Israel Deaconess Medical Center in Boston, where he developed and implemented numerous systems to improve clinical care delivery and patient engagement. He has earned degrees from Brown University, Ohio State University and the Harvard School of Public Health, and trained at Boston City Hospital and Boston’s Beth Israel Hospital. Sands currently holds an academic appointment at Harvard Medical School and maintains a primary care practice in which he makes extensive use of health IT. He works as a consultant for a variety of innovative companies. Sands is the recipient of numerous health IT awards, has been elected to fellowship in both the American College of Physicians and the American College of Medical Informatics, and is a founder and co-chair of the board of the Society for Participatory Medicine. In 2009, he was recognized by HealthLeaders Magazine as one of “20 People Who Make Healthcare Better.”
Sincerely,

Disclaimer:

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FOURTEEN THOUSAND USD BY A THIRD PARTY, LEGENDS MEDIA LLC  FOR A ONE DAY BTCY AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

OUR NEW PROFILE IS: (NASDAQ: KSPN)

Kaspien Logo (PRNewsfoto/Kaspien Holdings Inc.)

 

OUR NEW PROFILE IS: (NASDAQ: KSPN)

150 Employees, Serving 5,000 Brands in 20 Countries

The Entire Float is Under 4Million According to Yahoo Finance

Yahoo Also Has Revenues Over $130 Million for 2022

  ______________

Hello Everyone,

We have another low float profile for todays session. Pull up KSPN Immediately and start your research.
Kaspien Holdings Inc. (f/k/a Trans World Entertainment Corporation) (NASDAQ:KSPN) is a leading ecommerce marketplace growth platform, offering an expanding suite of software and services to help brands grow on Amazon, Walmart, Target, eBay, and other online marketplaces. Founded in 1972 as a brick-and-mortar retailer and rebranded as Kaspien in 2020, the Company has spent the last decade building and utilizing proprietary technologies for brand protection, marketing optimization, and fulfillment efficiency to generate rapid revenue growth for its partners. Through innovative strategies and best-in-class technologies, Kaspien has earned the trust of many leading brands, including 3M, Strider Bikes, and ZippyPaws. For more information, visit kaspien.com.

NEWS

MANAGEMENT

Brock Kowalchuk

INTERIM CHIEF EXECUTIVE OFFICER
Brock provides financial thought leadership to Kaspien, drawing on his background in funding, trading, and strategy at Goldman Sachs to spur meaningful improvements across the company. Brock’s non-traditional finance background of aerospace engineering and data science equips him with a unique lens from which to question the status quo and drive financial performance.

Lisa Wideman

CHIEF PEOPLE OFFICER
Lisa maintains a keen focus on the Human Resources Mission Statement: “To Maximize the Potential of our Biggest Asset – Our Employees.” With over 15 years in human resources, Lisa brings innovative ways to drive employee engagement and ensure a positive experience throughout the employee lifecycle.

Ed Sapienza

CHIEF FINANCIAL OFFICER
Ed began his career with Kaspien Holdings in 1993 and has served in positions of increasing responsibility, including Manager and Director of External Reporting, Director of Financial Planning, and Vice President of Strategy & Finance, along with being the Company Secretary before his most recent promotion to Chief Financial Officer in 2018.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.WE HAVE NOT BEEN COMPENSATED TO COVER KSPN AND DO NOT OWN ANY SHARES OF THE COMPANY. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.